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ABSTRACT 
The activation of tumor suppressor proteins, as p53, constitutes one of the several 
cellular mechanisms to protect human cells. Upon stress signals, p53 acts as a 
transcription factor, inducing the expression of several downstream targets responsible for 
the antiproliferative activity of p53. The growth-suppressive activity of p53 is tightly 
controlled by interaction with two negative modulator proteins, MDM2 and MDMX, which 
are overexpressed in about half of all human tumors. Inhibition of p53:MDM2/MDMX 
interaction may reactivate the p53 pathway and represent an alternative therapeutic 
strategy for cancer therapy. The elucidation of the crystal structures of p53 in complex 
with MDM2 and MDMX has led to the identification of several classes of small-molecule 
disruptors with favorable drug-like properties. Xanthone derivatives have been reported as 
promising anticancer agents with the ability to disrupt p53:MDM2 interaction. In fact, the 
naturally-occuring xanthones, α-mangostin and gambogic acid, and the synthetic 
derivatives pyranoxanthone LEM1 exhibited potent cytotoxic activity against several 
human tumor cell lines accompanied by an inhibitory effect on p53:MDM2 interaction. 
Overall, the xanthone scaffold has revealed to be promising for the search of new small-
molecule disruptors of p53:MDM2 interaction. 
In this dissertation, the recently developed synthetic pathway of the 3,4-dimethoxy-
9-oxo-9H-xanthene-1-carbaldehyde (LEM2) resulted in improved reaction yields when 
compared to previous synthetic pathway. Based on the pattern of substitution of LEM2 
derivatives, a potent inhibitor of p73:MDM2 interaction, and on the amine moiety of known 
p53:MDM2 inhibitors, a molecular hybridization strategy was followed to obtain new 
potential p53:MDM2 disruptors with drug-like properties and antitumor activity. By a 
reductive amination procedure, a library of aminoxanthone derivatives of LEM2 was 
successfully synthesized. The optimization of the reaction conditions was accomplished 
by using sodium triacetoxyborohydride and tetrahydrofuran as a reducing agent and 
solvent, respectively. Eleven new aminoxanthone derivatives were obtained and their 
structures were elucidated by spectroscopic techniques, including NMR (1H and 13C), IR 
and mass spectrometry. Docking studies were carried out to rank the aminoxanthones 
according to their binding affinity towards MDM2. These studies have shown a higher 
binding affinity of these derivatives against MDM2 when compared to the respective 
precursors and a similar binding affinity with known small-molecule disruptors of 
p53:MDM2 interaction. Using yeast-screening assays, the inhibitory activity of the 
aminoxanthones on p53:MDM2 interaction was investigated. No significant effects were 
observed on the growth of yeast cells co-expressing p53 and MDM2 proteins after the 
 xvi 
 
treatment with compounds. Further studies on p73:MDM2 may disclose potential inhibitors 
of p73:MDM2 interaction.  
 These studies will contribute to the knowledge of structural requirements for the 
construction of novel potent and selective small-molecule p53/p73 activators with 
antitumor activity. 
 
Keywords: antitumor activity, MDM2, molecular hybridization, p53, p73, reductive 
amination, xanthone. 
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RESUMO 
A ativação de proteínas supressoras tumorais, como a p53, constitui um dos 
diversos mecanismos celulares de proteção das células humanas, em resposta a sinais 
de stress intrínsecos e extrínsecos. A proteína supressora tumoral p53 atua como um 
fator de transcrição e estimula a expressão de diversas proteínas responsáveis pela 
atividade antiproliferativa da p53. A atividade supressora do crescimento associada à p53 
é controlada pela sua interação com duas proteínas, MDM2 e MDMX, que estão 
sobreexpressas em cerca de metade dos tumores humanos. O bloqueio da interação 
p53:MDM2/MDMX permite a reativação da p53 e representa uma estratégia terapêutica 
promissora para o tratamento de tumores. A elucidação estrutural por cristalografia de 
raios X da p53 complexada com cada uma das proteínas MDM2 e MDMX tem permitido a 
identificação de diversas classes de inibidores da interação p53:MDM2/MDMX com 
propriedades drug-like favoráveis. Os derivados xantónicos têm sido documentados como 
agentes antitumorais promissores e com capacidade de bloquear a interação p53:MDM2. 
De facto, as xantonas naturais, α-mangostin e ácido gambógico, e o derivado xantónico 
sintético, piranoxantona LEM1 exibiram uma atividade citotóxica marcada quando 
testadas em várias linhas celulares tumorais humanas, um efeito mediado por uma 
inibição na interação p53:MDM2. De uma forma geral, o núcleo xantónico tem-se 
revelado promissor na pesquisa de novas pequenas moléculas inibidoras da interação 
p53:MDM2. 
Nesta dissertação, a via de síntese do 3,4-dimethoxi-9-oxo-9H-xantene-1-
carbaldeído (LEM2) recentemente desenvolvida resultou numa melhoria do rendimento 
da reação de síntese quando comparado com o da via de síntese anteriormente 
existente. Tendo como base o padrão de substituição dos derivados do LEM2, um 
potente inibidor da interação p73:MDM2, e a porção amina de inibidores conhecidos da 
interação p53:MDM2, foi seguida uma estratégia de hibridização molecular com o objetivo 
de obter novas moléculas inibidoras da interação p53:MDM2 com propriedades 
farmacocinéticas favoráveis. A otimização das condições de reação foi conseguida 
através da utilização de triacetoxiboroidreto de sódio e tetraidrofurano como agente 
redutor e solvente, respetivamente. Através de um processo de aminação redutiva, foi 
sintetizada uma biblioteca de derivados aminoxantónicos do LEM2. Onze derivados 
aminoxantónicos recém-sintetizados foram elucidados estruturalmente por técnicas 
espectroscópicas, incluindo RMN (1H e 13C), IV e espetrometria de massa. Estudos de 
docking foram realizados de modo a classificar os derivados aminoxantónicos de acordo 
com a afinidade de ligação à proteína MDM2. Estes estudos demonstraram que os 
 xviii 
 
derivados aminoxantónicos têm uma maior afinidade de ligação a MDM2 do que os 
respetivos precursores e uma afinidade de ligação semelhante à de pequenas moléculas 
inibidoras da interação p53:MDM2 já conhecidas. Recorrendo a ensaios de screening 
com levedura, a atividade inibitória dos derivados aminoxantónicos na interação 
p53:MDM2 foi investigada. Não foram observadas alterações significativas na 
percentagem de crescimento de leveduras que expressam as proteínas p53 e MDM2 
após o tratamento com os compostos. Estudos posteriores envolvendo a interação 
p73:MDM2 poderão resultar em potenciais inibidores desta interação. 
Estes estudos poderão contribuir para o conhecimento dos requisitos estruturais 
mais favoráveis para a síntese de pequenas moléculas ativadoras da p53/p73 mais 
potentes e seletivas, com promissora atividade antiumoral. 
  
Palavras-chave: atividade antitumoral, aminação redutiva, hibridização molecular, 
MDM2, p53, p73, xantona. 
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OUTLINE OF THE DISSERTATION 
The present dissertation consists of six chapters. This dissertation involves three 
main areas of research: synthesis of formylated xanthone LEM2 and their aminoxanthone 
derivatives, docking simulation studies of these derivatives against MDM2 and the 
evaluation of their inhibitory activity on p53:MDM2 interaction. 
CHAPTER 1 – INTRODUCTION 
 
The introductory chapter of the present dissertation is divided in two sections. In 
the first part, a general review about biological functions of p53 and the influence 
of two negative protein modulators, MDM2 and MDMX, in p53 activity and function 
will be discussed as well as the structural requirements for the identification of 
p53:MDM2 and p53:MDMX disruptors. Also, a brief reference will be given to the 
isoforms of p53 protein. In the second part, an introduction to xanthone derivatives 
will be given and their promising inhibitory activity on p53:MDM2 will be 
highlighted.  
 
CHAPTER 2 – AIMS 
 
Herein, the main objectives of the present dissertation are described. 
 
CHAPTER 3 - RESULTS AND DISCUSSION 
 
Results are subdivided in three sections. In the first part, the different reaction 
steps for the synthesis of carbaldehydic xanthone LEM2 will be described as well 
as its structural elucidation. In the second part, the synthesis and the structure 
characterization of aminoxanthone derivatives of LEM2 will be presented. In the 
third part, the results concerning the docking simulation studies of these 
derivatives against MDM2 are discussed and preliminary results concerning the 
inhibition of p53:MDM2 interaction will be presented. The biological assay was 
performed with the assistance of Master Ana Sara Gomes and with the supervision 
of Prof. Lucília Saraiva at UCIBIO, Laboratory of Microbiology, FFUP.     
 
CHAPTER 4 – CONCLUSIONS 
 
This chapter includes the general conclusions of the present dissertation. 
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CHAPTER 5 - MATERIAL AND METHODS 
 
In this chapter, the experimental procedures for the synthesis and structure 
characterization of the new synthesized derivatives of LEM2 will be detailed. Also, 
the conditions applied for the docking studies and biological tests will be described. 
 
CHAPTER 6 – REFERENCES 
 
The references will be presented at the end of this dissertation. The references 
followed the American Chemical Society style guide. The main bibliographic 
research motors were ISI Web of Knowledge, from Thomson Reuters, Scopus, 
and Google. 
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CHAPTER 1 - INTRODUCTION 
1.1. The p53 tumor suppressor protein  
The p53 tumor suppressor protein is encoded by the TP53 gene1, which is span 
about 20 kb of DNA2 and is located on the short arm of chromosome 173. It acts mainly as 
a transcription factor and is biologically active as a homotetramer containing 393 amino 
acid residues each monomer4 (Figure 1).  
 
Figure 1 - Crystal structure of self-assembled p53 tetramer bound to DNA (PDB code 3KMD). 
Structurally, p53 is characterized by a modular domain which consists of folded 
DNA-binding and tetramerization domains. The NH2-terminal region contains a 
transactivation domain (TAD) followed by a proline-rich region (PRR). A DNA-binding 
domain (DBD) is in the middle of the protein and connected to oligomerization domains 
(OD) through a flexible linker region. A regulatory domain is located at the COOH-terminal 
region4 (Figure 2). This structure allows the tetrameric p53 protein, on binding to DNA, to 
regulate the expression of several genes responsible for tumor suppressor effect of p531,5. 
 
 
Figure 2 - The p53 protein contains, in the NH2-terminal region, a transactivation domain (TAD) 
followed by a proline-rich region (PRR). The DNA-binding domain (DBD), located in the middle of the protein, 
is linked to the oligomerization domain (OD) (adapted from 
4
). 
 
1.1.1. Biological functions of p53 
Under physiological (unstressed) conditions, p53 is unstable with a short half-life 
and is held in an inactive state that undergoes to a significant increase in its activity and 
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stability in response to various stress signals6. Upon DNA-damaging agents, the p53 acts 
as a transcription factor, inducing the expression of several downstream targets which 
play an important role in regulation of cell cycle, apoptosis, DNA repair, senescence and 
angiogenesis7. Therefore, upon stress signals, the activation of p53 can suppress the 
tumor development and growth, preventing damaged cells from multiplying and passing 
mutated genes with oncogenic potential to the next generation8. For that reason, it is not 
surprising that p53 is considered “the guardian of genome” as it contributes to genome 
integrity9.  
A defective p53 regulation may hinder p53 activation, resulting in inadequate tumor 
suppression and in an uncontrollable proliferation of cancer cells10. However, the growth-
suppressive and proapoptotic activity of p53 is lethal for normal cells if left uncontrolled. 
Thus, p53 activity must be tightly regulated in order to maintain tissue homeostasis11. 
 
1.1.2. Regulation of p53 
Under normal physiological conditions and during stress, the cellular level and 
activity of p53 are subjected to tight control by several modulators10. The two main 
negative regulatory proteins, murine double minute 2 (MDM2) and X (MDMX; also known 
as MDM4), are crucial for the regulation of p53 function11 (Figure 3).  
 
 
Figure 3 – Crystal structures of oncoproteins MDM2 (PDB code 1YCR) and MDMX (PDB code 3DAC). 
 
Human MDM2 and MDMX are structurally related oncoproteins composed by 491 and 
490 amino acids respectively, with three well-conserved domains: an NH2-terminal domain 
which is important for binding to the NH2-terminal region of p53, a zinc finger domain and 
a COOH-terminal really interesting new gene (RING) domain (Figure 4). MDM2 and 
MDMX also contain a region rich in acidic residues, without any significant sequence 
conservation12.
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Figure 4 – Similarity of structural domains of MDM2 and MDMX oncoproteins (adapted from 
11
). 
 
1.1.2.1. The role of MDM2 in negative regulation of p53 
 
The MDM2 gene was initially discovered in DNA associated with paired acentric 
chromatin bodies, termed double minutes, in spontaneously transformed mouse 3T3 
fibroblasts13. It was found that MDM2 and p53 mutually regulate each other through an 
autoregulatory feedback loop7. The physiological relevance of this autoregulatory loop 
was shown by genetic evidence that embryonic lethality of MDM2-null mice can be 
rescued only upon deletion of TP53 gene14. In fact, MDM2 is a transcriptional target of 
p53, which attenuates p53 activity through diverse mechanisms7 (Figure 5).  
Under stress conditions, the high p53 levels in nucleus stimulate the MDM2 
transcription through binding of p53 at the p53-binding domain of MDM2 gene. This up-
regulation results in an increase of the MDM2 levels. Consequently, MDM2 physically 
interacts with the NH2-terminal domain of p53
15. The p53:MDM2 interaction results in a 
partial overlapping of TAD (located at NH2-terminal region of p53) and in an inactivation or 
attenuation of transcriptional function of p5310.  
The growth suppressive activity of p53 can also be controlled by its ubiquitination 
and proteossomal degradation. Protein ubiquitination involves three ATP-dependent 
enzymes in a sequential reaction: an ubiquitin activating enzyme (E1), an ubiquitin 
conjugating enzyme (E2) and an ubiquitin protein ligase (E3). E1 forms a thioester bond 
between its active site cysteine residue and glycine residue of ubiquitin. E1-ubiquitin 
complex is transferred to E2 by transthioesterification. Then, E3 catalyzes the final step of 
the ubiquitination cascade. This enzyme binds to the E2-ubiquitin complex and enables 
the formation of an isopeptide linkage between the COOH-terminal region of ubiquitin and 
the lysine residue in the target protein. Once four or more ubiquitin molecules (poly-
ubiquination) are attached, the modified protein is recognized and degraded by the 26S 
proteasomes16. MDM2 belongs to the family of E3 ubiquitin ligases that contain a RING 
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domain. These enzymes are structurally defined by cross-branched active site histidine 
and cysteine residues bound to two zinc ions. This RING domain is located at the COOH- 
terminal region of MDM2 and shows to have a crucial role in its E3 ligase activity. This 
oncoprotein mediates the direct transfer of ubiquitin from an E2 enzyme (ubiquitin 
conjugating enzyme) onto lysine residues located at the COOH-terminal domain of p53, 
catalyzing its ubiquitination10, 16. 
 
Figure 5 - Regulation of p53 by MDM2 and MDMX through autoregulatory feedback loop. Under both 
physiological and during stress, the cellular level and activity of p53 are subjected to tight control mainly by 
MDM2 and MDMX by several mechanisms: MDM2 interacts with NH2–terminal region of p53 leading to the 
inactivation of p53 transcriptional activity and also enables nuclear export of p53, keeping it away from nuclear 
DNA; MDM2 mediates p53 degradation via the ubiquitin-proteasome pathway (adapted from 
8
). 
 
Lastly, MDM2 facilitates export of p53 out of the cell nucleus, via MDM2 RING 
finger domain, making p53 inaccessible to targeted DNA for transcription7, 17. 
This autoregulatory negative feedback loop between p53 and MDM2 is essential 
for restricting p53 activity in unstressed cells and for eliminating accumulated p53 upon 
stress signals17.  
 
1.1.2.2.  The role of MDMX in negative regulation of p53.  
 
The MDMX protein has emerged only recently as a critical p53 negative regulator 
and is a close homolog of MDM218. Like MDM2, the embryonic lethal phenotypes of 
MDMX-null mice can be rescued by simultaneous knockout of TP53 gene19   As referred 
above, MDM2 and MDMX share a high sequence homology mainly in their p53-binding 
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domains and RING finger domains7. MDMX acts cooperatively with MDM2, potentiating its 
ubiquitin ligase activity and enhancing p53 degradation. Both MDM2 and MDMX regulate 
p53 transcriptional activity through interactions mediated by their NH2-terminal domains 
and the NH2-terminal TAD of p53
20. Despite sharing high sequence and structural 
homology, MDM2 and MDMX regulate p53 by distinct manners. While MDM2 promotes 
the down-regulation of p53 activity by promoting its ubiquitination and subsequent 
degradation, MDMX abolishes the p53 function by sequestering it into an inactive 
p53:MDMX complex21. Although MDMX is not active as an E3 ligase, it can form 
heteroligomers with MDM2, acting as a negative regulator of p5319. 
 
1.1.3. The isoforms of the p53 protein: p63 and p73 
 
Two p53-related genes, p63 and p73, were first identified in 1997 and exhibit, like 
p53, the aminoterminal transactivation domain (TAD) followed by a proline rich region 
(PRR), the central DNA-binding domain (DBD), and the carboxy-terminal oligomerization 
domain (OD)22 (Figure 6). In p63 and p73, there is an additional COOH-terminal sterile-α 
motif. The high structural and functional homology between p53, p63 and p73 proteins, 
particularly in the DNA binding domain, allows the transactivation of p53-responsive 
genes by p63 and p73, inducing apoptosis and cell-cycle arrest23. These three proteins 
form a family of transcription factors which are not functionally entirely redundant and so 
that each p53 famile member has its own unique biological functions24. The p53 gene 
family members express multiple mRNA variants due to multiple splicing and alternative 
promoters. Therefore, p53 gene family members express different forms of p53 protein 
containing different domain of the protein (isoforms)23.  
The human p63 gene express at least three alternatively spliced COOH-terminal 
isoforms (α, β, γ), while the p73 gene express at least seven alternatively spliced COOH-
terminal isoforms (α, β, γ, δ, ε, ζ, η) and four alternatively spliced NH2 terminal isoforms
25. 
Both p63 and p73 genes can be transcribed from one promoter upstream of exon 1, which 
leads to the expression of TAp63 and TAp73 (transcriptionally proficient), and one 
promoter located on intron 3, that leads to the expression of ΔNp63 and ΔNp73 isoforms 
lacking transactivation domain (transcriptionally inactive)26.  
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Figure 6 – Crystal structures of p63 (PDB code 1RG6) and p73 (PDB code 1COK). 
 
 In a similar manner of p53, p73 is also regulated by its interaction with MDM2 and 
MDMX. However, unlike p53, MDM2 does not promote p73 ubiquination and 
degradation27. It was found that MDM2 inhibits p73 transcriptional activity by preventing its 
interaction with the coactivators p300/CBP and RNA-polymerase associated factors28.  
 Relatively to p63, it was found that this protein weakly interacts to both MDM2 and 
MDMX29,29b. 
 The p53 family proteins have a central role in the control of cell proliferation and 
death, constituting a valuable therapeutic targets for cancer therapy.  
 
1.1.4. p53, a valuable target for cancer treatment 
 
As p53 has the ability of suppressing the development and propagation of 
damaged cells to protect the normal tissues, it’s not surprising that the inactivation of p53 
function may represent almost an universal feature of human cancer cells. In fact, 
approximately 50% of all human tumors are caused by mutations in the TP53 gene. It has 
been reported that the majority of these mutations occurs in the DBD region which is 
responsible to the specific DNA-binding function of p53. The main functional deficiency of 
p53 mutation is the specific DNA-binding ability and its transcriptional activity, which 
directly causes the attenuation of antiproliferative activity of p5310. In the remaining 50%, 
human cancer cells exhibit a p53 wild-type phenotype. However, an aberrant p53 
regulation and signaling of p53 pathway, which is caused by an overexpression of 
oncoproteins MDM2 and MDMX, stimulates the cell growth and tumorigenesis, 
compromising the tumor suppressor effect of p5330. Therefore, the p53 protein has 
become one of the most important therapeutic targets in cancer treatment9. 
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1.1.5. Therapeutic strategies for cancer treatment: activation of p53-
dependent pathway 
 
Several therapeutic targets have been developed for treatment of wild-type p53 
and mutant p53 tumors to restore p53 activity and function. For cancer cells which 
express mutant p53, restoration of p53 wild-type function may result in considerable 
therapeutic responses. In this case, the following strategies can be applied: (1) gene 
therapy with wild-type p53 and (2) reactivation of mutant p53 with peptides and small-
molecules. On the other hand, when tumors express wild-type p53, efforts should be 
aimed on the stabilization of p53 protein and activation of p53-dependent pathway. The 
following therapeutic strategies can be used: (1) blockade of MDM2 expression, (2) 
inhibition of MDM2 ubiquitin ligase activity and (3) disruption of p53:MDM2/MDMX 
interaction10  
 
1.1.6. Targetting p53:MDM2/MDMX interaction as a promising approach for 
cancer therapy 
 
The p53:MDM2/MDMX interface is defined as a protein-protein interaction (PPI). 
PPIs have proved to be challenging for drug discovery since the interface between two 
proteins is generally large, flat and involve interactions with a high number of amino acid 
residues from each protein30. These characteristics appear to be unfavorable on 
identification of compounds with drug-like properties10. In fact, small-molecules are 
preferred in drug discovery, comparing with peptide, peptidomimetics and macromolecular 
inhibitors, because of several advantages, such as better stability and bioavailability 
(especially oral bioavailability) and enhancement of absorption, distribuition, metabolism 
and excretion (ADME) characteristics10, 30. However, it has been shown that though these 
two proteins make many contacts with each other, there is generally a small pocket of a 
few amino acid residues that make up for the majority of the binding energy. In the context 
of p53:MDM2 and p53:MDMX interaction, just three amino acid residues of p53, Phe19, 
Trp23 and Leu26 contributed to a large extent for the physical interaction and binding 
energy of the p53:MDM2/MDMX complex5.  
 
1.1.7. The p53:MDM2/MDMX interaction: structural requirements 
 
 In 1996, it was published a high resolution crystal structure of MDM2 in complex 
with a short p53-peptide (NH2-terminal residues 15-29)
31 and in 2008, the crystal structure 
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of human MDMX bound a peptide derived from human p53 NH2-terminal domain was 
elucidated32 (Figure 7). The crystal structures of both p53:MDM2 and p53:MDMX 
complexes revealed these interactions are mediated by the three key hydrophobic 
residues in p53 (Phe19, Trp23 and Leu26) and a hydrophobic surface groove in MDM2 
and MDMX proteins. Therefore, the p53:MDM2 and p53:MDMX interaction result in 
formation of complexes which display similar binding features9. In spite of the similarity of 
most residues in the MDM2 and MDMX binding pockets, some amino acid residues 
located around the Leu26 binding pocket are different, leading to distinct shape and size 
of MDMX groove comparing to the MDM2 groove. In fact, the presence of MDMX amino 
acid residues Met53 (Leu54 in MDM2), Leu98 (Ile99 in MDM2), Leu102 (Ile103 in MDM2) 
and Pro95 (His96 in MDM2) resulted in smaller binding groove in MDMX compared to 
MDM233.  
 
Figure 7 – Hydrophobic amino acid residues of p53 that contribute to large extent for the binding energy of 
p53:MDMX (PDB code 3DAC) and p53:MDM2 interaction (PDB code 1YCR). 
 
The knowledge of crystallographic structures of p53 in complex with MDM2 and 
MDMX has led to the identification of several classes of promising small-molecule 
inhibitors with antitumor effectiveness. 
 
1.1.8. Small-molecule inhibitors of p53:MDM2 and p53:MDMX interaction 
 
Low-molecular weight inhibitors are preferred as drug candidates due to their 
favorable pharmacokinetic (PK) properties in alternative to peptides or macromolecular 
inhibitors. Upon the realization that impairing the interaction between p53 and 
MDM2/MDMX are dependent on interactions of “three finger pharmacophore” with 
hydrophobic clefts of MDM2 and MDMX, efforts have been made in order to find out and 
develop potent small molecule antagonists of p53:MDM2 and p53:MDMX interaction with 
 11 
   
potential antitumor activity. In this section, the most relevant classes of small molecule 
inhibitors of p53:MDM2 (Table 1) and p53:MDMX (Table 2) interactions will be presented 
as well as some information about strategies used in their discovery and their PK profile 
and progress in the pipeline. Comparing the two tables which represent the different 
classes of small molecule inhibitors of p53:MDM2 and p53:MDMX interaction, it can be 
observed that only a few number of MDMX inhibitors exists when compared to the high 
number of p53:MDM2 interaction disruptors. In fact, there are several classes of MDM2 
antagonists which have shown not only to be potent in inhibiting the mentioned interaction 
but also exhibited a selective antitumor activity in some cancer cell lines with a wild-type 
p53.  
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Table 1 – Classes of small-molecule inhibitors of p53:MDM2 interaction. 
Chemical Family: Benzodiapedinedione 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
TDP222669 
TDP521252 
TDP665759 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
 
Temperature-dependent protein unfolding 
assay (ThermoFluor microcalorimetry) 
 
Fluorescence polarization assay 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
 
 
TDP222669 showed poor cell membrane 
permeability, a rapid clearance and almost no 
bioavailability. 
 
TDP521252 and TDP665759 resulted from 
optimization of PK properties of TDP222669, 
showing an enhanced bioavailability and cell 
permeability in a CACO-2 assay. 
 
 
 
 
 
 
 
 
 
 
 
 
TDP521252 and TDP665759 are under 
preclinical trials. 
References 
 
9, 10, 17, 34, 35, 36
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(continuing) 
Chemical Family: Chromenotriazolopyrimidine 
Structure of lead compound Relevant Members 
 
 
 
 
Chromenotriazolopyrimidine 1 [(6R,7S)-6,7-
bis(4-bromophenyl)-12-methyl-7,9,10,11,11a,12 
-hexahydro-6H-chromeno[4,3-d][1,2,4]triazolo[ 
1,5-a]pyrimidine] 
 
Chromenotriazolopyrimidine 2 [2-((6R,7S)-6,7-
bis(4-bromophenyl)-6H-chromeno[4,3d][1,2,4] 
triazolo[1,5-a]pyrimidin-12(7H)-yl)acetic acid] 
 
Chromenotriazolopyrimidine 3 [5-((6R,7S)-6,7-
bis(4-bromophenyl)-6H-chromeno[4,3-d][1,2,4] 
triazolo[1,5-a]pyrimidin-12(7H)-yl)pentanoic 
acid] 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
 
 
 
Homogenous time resolved fluorescence 
(HTRF) assay  
 
 
 
 
Pharmacokinetic profile In the pipeline 
 
 
 
Chromenotriazolopyrimidine 1 displayed poor 
pharmacokinetic properties. In rat, this 
compound exhibited a low solubility in PBS and 
moderate-to-high clearance and a low oral 
bioavailability (23%). An improvement on PK 
profile has led to the identification of the 
derivatives 2 and 3, which are more potent and 
metabolically stable. In rat, derivative 2 
exhibited a high clearance and derivative 3 had 
shown a low clearance and an improved oral 
bioavailability. 
 
 
 
 
 
 
 
 
 
 
 
 
- 
References 
 
37
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(continuing) 
Chemical Family: Cis-imidazoline 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
Nutlin-1 
Nutlin-2 
Nutlin-3 
RG7112 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
 
 
 
 
Biacore surface plasmon resonance assay 
 
 
 
 
Pharmacokinetic profile In the pipeline 
 
 
 
Pharmacological properties of nutlins were 
inadequate for clinical development. The 
imidazoline core of nutlins can be converted to 
the inactive imidazole form. 
 
RG7112 resulted from optimization of nutlins 
structure for clinical use. This compound has 
good oral bioavailability. Introduction of methyl 
groups contributes to a greater structural rigidity 
in imidazoline scaffold and blocks metabolic 
conversion to the inactive imidazole form. 
 
 
 
 
 
Nutlin-3a is in phase I clinical trial for the 
treatment of retinoblastoma. 
 
 
RG7112 completed phase I clinical studies in 
advanced solid tumors and hematological 
neoplasms. 
 
 
 
 
 
 
 
 
 
References 
 
9, 10, 35, 38, 39, 40, 41
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(continuing) 
Chemical Family: Diphenylbutylpiperidine 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
Fluspirilene 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
 
 
Virtual screening 
 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
Fluspirilene is a long-acting injectable 
antipsychotic drug which showed an inhibitory 
activity on p53:MDM2 interaction in human 
tumor cell lines.  
 
 
 
 
 
 
 
References 
 
42
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(continuing) 
Chemical Family: Isoindolinone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
NU8165 
NU8231 
 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
 
 
NMR binding assay 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
Further studies to address potency, selectivity 
and drug-like properties for this class of 
inhibitors are ongoing. 
 
 
 
 
 
 
- 
References 
 
43, 44 
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(continuing) 
Chemical Family: Isoquinolinone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NXN-7 
NXN-561 
NVP-CGM097 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
NMR binding assay 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
NXN-7 was found to have poor in vivo solubility. 
 
NXN-561 displayed increased solubility and 
improved cellular activity. 
 
NVP-CGM097 is soluble in DMSO and not in 
water. 
 
 
 
 
 
 
 
NVP-CGM097 is undergoing a phase I dose 
scalation study in adult patients with advanced 
solid tumors. 
 
 
 
 
 
References 
 
10, 35, 45
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(continuing) 
Chemical Family: Morpholinone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AM-8735 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
Design based on piperidinone scaffold 
 
HTRF assay 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
 
 
 
 
AM-8735 exhibited metabolic stability in human 
hepatocytes and exhibited low clearance in 
rats. AM-8735 is preferentially metabolized by 
oxidation pathways 
 
 
 
 
 
 
 
 
- 
 
 
 
References 
 
46
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(continuing) 
Chemical Family: Piperidinone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
AM-8553 
AMG-232 
AM-6761 
AM.7209 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
EdU cell proliferation assay 
 
HTRF assay 
 
Pharmacokinetic profile In the pipeline 
AM-8553 had an oral bioavailability of 100% in rats and 
12% in mice. It had a reduced liability in human 
pregnane X receptor (hPXR), CYP3A4 and time-
dependent inhibition (TDI) assays. This compound 
presented a low human hepatocyte intrinsic clearance 
with a high volume of distribution and a long human 
half-life (>12h). 
 
AMG-232 displayed low intrinsic clearance in human 
hepatocytes and in vivo clearance in rats. This 
compound was found to have minimal liabilities in the 
CYP inhibition, TDI of CYP3A4, and PXR induction 
assays. AMG-232 is preferentially metabolized to an 
acylglucuronide derivative when incubated in rat, dog, 
cyno and human hepatocytes. 
 
AM-6761 exhibited low intrinsic clearance in human 
hepatocytes and low CYP3A4 TDI activity. This 
compound exhibited improved metabolic stability in 
mouse and rats and increased oral bioavailability. It is 
cleared primarily by oxidation pathways. 
 
AM-7209 displayed a low intrinsic clearance in human 
hepatocytes and a reduced liability hPXR, CYP3A4 and 
TDI assays. An oxidation pathway is the preferred 
metabolic route of AM.7209 in dog, cyno, rat and human 
hepatocytes. 
 
 
 
AM-8553: No information on the advancement 
of this series to clinical settings is available yet. 
 
AMG-232 is undergoing phase I clinical studies 
in acute myeloid leukemia and in advanced 
solid tumors. It is also undergoing phase Ib/IIa 
in metastatic melanoma. AMG-232 is 
undergoing phase I alone and in combination 
with Trametinib in acute myeloid leukemia. 
 
 
 
References 
44, 46, 47, 48, 49, 50, 51 
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(continuing) 
Chemical Family: Pyrrolidine 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
RG7388 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
 
HTRF assay 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
RG7388 presented oral bioavailability (80%), 
metabolic stability and low clearance. 
 
 
 
RG7388 is undergoing clinical investigation in 
solid and hematological tumors (phase I). It is 
also undergoing in patients with polycythemia 
vera and essential thrombocythemia.   
 
 
 
 
References 
 
52
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(continuing) 
Chemical Family: Pyrrolidinone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
PXN-727 
PXN-822 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
Fluorescence polarization assay 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
PXN-727 has low toxicity and presents a better 
bioavailability when compared to nutlin-3. 
 
 
PXN-727 and PXN-822 are undergoing 
preclinical studies. 
 
 
 
References 
 
35, 36, 53, 54, 55
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(continuing) 
Chemical Family: Quinolinol 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
NSC 66811 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
Fluorescence polarization assay 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
NSC 66811 is cell-permeable. 
 
Further investigation of quinolinol derivatives in 
mouse model is still undergoing. 
 
 
References 
 
10, 49, 56
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(continuing) 
 
Chemical Family: Spiro-(oxindole-3,3’-pyrrolidine) 
Structure of lead compound Relevant Members 
 
 
 
 
 
MI-63 
MI-147 
MI-219 
MI-319  
MI-888 
SAR405838 
MI-1061 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
De novo design 
Fluorescence polarization assay 
Pharmacokinetic profile 
Presence of fluorine group on the phenyl ring of MI-63 increased its metabolic stability. However, it was found to be 
unsuitable due to its poor PK properties and oral bioavailability 
 
MI-219 displays highly desirable PK properties and an improved oral bioavailability in mice. This compound also revealed 
minimal toxicity. 
MI-147 revealed to be more potent than MI-219 in cell growth inhibition and in induction of p53 activation with an improved 
oral bioavailability and low toxicity. 
 
Using wild type p53 xenograft of Capan-2, MI-319 revealed to be orally bioavailable, resulting in significant tumor growth 
inhibition without any observed toxicity in animals. No tumor inhibition was found in mutant p53 BxPC3 xenografts. 
 
MI-888 was found to be highly potent with an excellent oral PK profile and in vivo activity. This compound was capable of 
achieving complete and long-lasting tumor regression in animal models of human cancer upon oral administration without 
signs of toxicity. 
 
MI-888 revealed metabolic stability, which was confirmed in rat, mouse and human microssomes and an excellent oral 
bioavailability in rats. 
 
MI-1061 was orally bioavailable and  showed excellent chemical stability in mice. 
In the pipeline 
MI-147 is currently undergoing preclinical studies. 
 
MI-219 and MI-319 are undergoing preclinical studies. 
 
MI-888 is undergoing phase I clinical trials. 
 
SAR405838 is undergoing phase I study to assess safety on neoplasma malignancies and a phase I study in 
patients with advanced cancer when combined with Pimasertib. 
References 
10, 44, 45, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
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(continuing) 
Chemical Family: Spiro-(oxindole-3,3′-thiazolidine) 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
SM13 
 
ISA27 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
Structure-based design (design based on spiro-
oxindole derivatives) 
 
Antagonist induced dissociation assay (AIDA) 
 
ImmunoSet p53:MDM2 complex ELISA 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
- 
 
SM13 could be a good anticancer to be used in 
combination with common anticancer agents 
and can be used as a prototype molecule for 
the design of more potent spirothiazolidin-
based derivatives.  
 
References 
 
68, 69, 70
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(continuing) 
Chemical Family: Sulfonamide 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
NSC 279287 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
Structure-based design 
 
Pharmacophore-based virtual screening 
 
p53 luciferase reporter assay 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
- 
NSC 279287 exhibited low binding affinity to 
MDM2 and its potential as anticancer drugs has 
not been established yet. 
References 
 
71
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(continuing) 
Chemical Family: Terphenyl 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
Terphenyl 1 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
Fluorescence polarization assay 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
The presence of acid group contributed to its 
solubility in aqueous solution. 
The potential of terphenyl derivatives as 
anticancer drugs has not been established yet. 
References 
 
10, 72, 73 
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(continuing) 
Chemical Family: Xanthone 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
α-Mangostin 
 
Gambogic acid 
 
Pyranoxanthone LEM1 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
Virtual screening 
 
High-throughput screening by a yeast 
phenotypic assay 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
- 
Preclinical studies, pyranoxanthone LEM1 
represents a useful lead compound for the 
structure-based design of more potent drug-like 
analogs. 
References 
 
74, 75, 76 
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Table 2 – Classes of small-molecule inhibitors of p53:MDMX interaction. 
Chemical Family: Benzofuroxan 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XI-006 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
FRT-based recombinant technology 
 
Quantitative real time-PCR (qRT-PCR) assays 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
XI-006 exhibited low toxicity. 
 
Preclinical studies, XI-006 can be used as a 
lead compound for further development of a 
new class of therapeutic agents targeting 
MDMX. 
References 
 
36, 77  
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(continuing) 
Chemical Family: Pseudourea 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XI-011 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
qRT-PCR assays 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
 
XI-011 showed selectivity in decreasing viability 
of cancer cells without genotoxicity. 
XI-011 can serve as a lead compound for 
further development into a therapeutic agent for 
breast cancer treatments. 
References 
 
78 
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(continuing) 
Chemical Family: Pyrazolylidene 
Structure of lead compound Relevant Members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SJ-177250 
 
 
Drug discovery: strategy Drug discovery: assay 
 
 
 
 
 
 
 
 
 
 
 
Structure-based design 
 
 
MDMX high throughput fluorescence 
polarization assay 
 
Pharmacokinetic profile In the pipeline 
 
 
 
 
 
 
 
 
SJ-172250 exhibited chemical stability, thermal 
stability, undetectable redox activity and 
solubility, and low cell permeability. 
 
Preclinical studies: SJ-172250 represents a 
lead compound with a useful chemical scaffold 
for further optimization of MDMX inhibitors for 
treatment of human tumors which overexpress 
MDMX. 
 
References 
 
36, 79, 80 
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1.2. Xanthones: a promising scaffold for inhibition of p53:MDM2 
interaction 
 
Xanthone derivatives comprise a class of natural products orignally isolated from 
plants and microrganisms81. From the chemical point of view, xanthones are hetero-
tricyclic planar compounds which contain a dibenzo-ɣ-pyrone scaffold and they are 
structurally related with other compounds that contain ɣ-pyrone scaffold: flavonoids and 
chromones (Figure 8). 
 
Figure 8 - Scaffolds of different classes of secondary metabolites with a dibenzo-ɣ-pyrone.  
 
             Biossynthetically, xanthones are formed through conjugation of molecular 
percursors of acetate pathway (ring A) and shikimate pathway (ring B). According to 
nature of the substituents in the dibenzo-ɣ-pyrone scaffold, xanthone can be classified into 
five major groups: simple oxygenated xanthones, glycosylated xanthones, prenylated 
xanthones and their derivatives, xanthonolignoids, and miscellaneous xanthones. Simple 
oxygenated xanthones can be subdivided according to their degree of oxygenation into 
non-, mono-, di-, tri-, tetra-, penta- and hexaoxygenated derivatives82. A great interest has 
been given to the naturally-occuring xanthones because they have been a source of 
bioactive compounds with different types of substituents in different positions and with a 
large diversity of pharmacological activities83. Although natural products may represent an 
important source of new interesting scaffolds in Medicinal Chemistry, the biossynthetic 
pathway of xanthones only allows the presence of certain groups in specific positions of 
the xanthone scaffold81a. Since their biosynthetic pathways are a limiting factor for the 
structural diversity of naturally-occuring xanthones, the use of chemical synthesis 
increased the possibilities of obtaining new derivatives having different nature and position 
of the substituents on the xanthone scaffold84. Furthermore, the synthesis of more diverse 
and complex xanthonic compounds for biological activity allows more detailed structure-
activity relationship (SAR) studies.  
             Among the diversity of biological activities described for naturally-occuring and 
synthetic xanthones, their antitumor activity accompanied by an inhibitory activity on 
p53:MDM2 interaction has been widely reported. Among the naturally-occuring 
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xanthones, some compounds are remarkable anticancer agents via disruption of 
p53:MDM2 interaction: α-mangostin and gambogic acid (Figure 9). The prenylated 
xanthones α-mangostin and gambogic acid are obtained from the mangosteen fruit of 
Garcinia mangostana L. (Clusiaciae) and from a resin extracted from the Garcinia 
hanburyi tree (Clusiaceae), respectively85. Initially, the inhibitory activity of these natural 
products as potential inhibitors of the p53:MDM2 interaction was hypothesized based on 
previous studies that have shown a correlation between the cytotoxic activity of these 
xanthones and the activation of p53 pathway86. Based on a yeast-based approach, a 
effective procedure to search for p53:MDM2 inhibitors, α-mangostin and gambogic acid 
were found to revert the inhibitory effect of MDM2 on p53-induced growth inhibition and on 
p53-dependent transcriptional activity. The increase of p53-dependent transcriptional 
activity was confirmed in a MDM2-overexpressing human adenocarcinoma-derived MCF-
7 tumor cell line with wild-type p53. In contrast to wild-type p53, these xanthones had no 
impact on growth of yeast expressing mutant p53, suggesting that, as inhibitors of 
p53:MDM2 interaction, α-mangostin and gambogic acid may act on MDM2. Furthermore 
computational docking studies performed against MDM2 indicated that the binding affinity 
values for these two xanthones were similar to nutlin-3a, a known inhibitor of p53:MDM2 
interaction. Also the predicted binding model of these compounds indicate that these 
compounds adopted a pose that filled the binding site critical for interaction between the 
NH2 terminal domain of p53 with the respective binding site
74.         
 
 
Figure 9 – Chemical structures of naturally-occuring prenylated xanthones α-mangostin and gambogic acid. 
 
            Pyranoxanthone LEM1 was initially identified as a potential inhibitor of p53:MDM2 
interaction, employing a virtual screening strategy (Figure 10). With the virtual screening, 
the most promising MDM2 ligands were identified and their inhibitory activities as 
inhibitors of p53:MDM2 interaction were evaluated using yeast screening assays. Among 
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the tested xanthones, only LEM1 significantly reduced the MDM2 inhibitory effect on p53 
activity in yeast cells co-expressing p53 and MDM2 interaction without inducing cytotoxic 
effects on control yeast. Also, LEM1 reverted the MDM2 inhibitory effect on p53 
transcriptional activity. The molecular mechanism of action of LEM1 was corroborated in 
MDM2-overexpressing human tumor cell lines with a wild-type phenotype. In fact, LEM1 
selectively increased the p53-dependent transcriptional activity and induced the activation 
of p53-dependent pathway in HCT116 p53 +/+ cell line. Therefore, LEM1 represents a 
useful lead compound for the structure-based design of more potent drug-like 
derivatives75.  
 
Figure 10 – Chemical structure of pyraoxanthone LEM1. 
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CHAPTER 2 - AIMS 
Xanthone derivatives have been reported as promising antitumor agents and, in 
the last years, molecular modifications on xanthone scaffold were performed in order to 
obtain new and potent small-molecules with antitumor activity. In fact, some of the 
xanthones with antitumor activity have also shown to be potent inhibitors of p53:MDM2 
interaction: the naturally-occurring xanthones, α-mangostin and gambogic acid, and the 
synthetic xanthone LEM1.  
α-Mangostin and gambogic acid are naturally occurring prenylated xanthones 
which are isolated from the mangosteen fruit of Garcinia mangostana L. (Clusiaceae) and 
from the resin of Garcinia hanburyi Hook.f. (Clusiaceae), respectively. LEM1 is a 
prenylated xanthone synthetized by our research group (CEQUIMED-UP). The 
effectiveness of these molecules as promising antitumor agents with the ability to disrupt 
p53:MDM2 interaction was shown in yeast-screening assays and also in several human 
tumor cell lines74-75. Recently, 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2) 
has displayed an inhibitory activity on p73:MDM2 interaction in a p53-null human colon 
carcinoma tumor cell line expressing p73 (not p53 and p63)*. The carbaldehydic xanthone 
LEM2 may represent a promising anticancer agent to be explored in cancer therapy.  
Based on these considerations, the main aim of the present dissertation consisted 
in the synthesis of a library of aminoxanthone derivatives of LEM2 by a process of 
reductive amination (Figure 11).  
 
 
Figure 11 - Schematic representation of the main aims of the present dissertation. 
* Ramos, H., Leão, M., Soares, J., Raimundo L., Queiroz, G., Brandão, P., Pinto, M., Sousa, E., 
Saraiva, L.”LEM2: a new small-molecule inhibitor of the p73:MDM2 interaction”. Book of Abstracts-8
th
 
Meeting of Young Researchers of University of Porto, 13-15 May 2015, p.165.  
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To synthesize the diverse derivatives, a scale-up of the synthesis of carbaldehydic 
xanthone LEM2 was followed. The planning strategy consisted in applying a molecular 
hybridization approach. Based on known small-molecule inhibitors of p53:MDM2 
interaction, amine moieties of these inhibitors were selected for conjugation with the 
carbaldehydic xanthone LEM2. The introduction of these amines in the aminoxanthone 
derivatives simultaneously will present the combination of a priviliged moiety of antitumor 
activity (xanthone scaffold) and a pharmacophoric moiety of inhibitory activity on 
p53:MDM2 interaction (amine moiety).  
The amines used for reductive amination resulted from a selection of the amine 
moieties contained in the structure of known inhibitors of p53:MDM2 interaction (Figure 
12). The replacement of the carbonyl group of LEM2 by an amine moiety of the 
aminoxanthone derivatives may contribute to the establishment of additional interactions 
to the active site of MDM2, improving their binding affinity and their pharmacodynamic 
profile. Besides that, the introduction of an amine moiety may result in a potential 
enhancement of drug-like properties, as water solubility, a crucial requirement for the 
identification of promising drug candidates.    
 
Figure 12 – Selected amines from known p53:MDM2 inhibitors for reductive amination and respective 
p53:MDM2 inhibitors  
  
In silico studies were also performed with the objective of predicting and ranking 
the binding affinity of the aminoxanthone derivatives against MDM2. To confirm the 
docking results, the investigation of the potential of these derivatives to disrupt p53:MDM2 
interaction was assessed using yeast-screening assays.   
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CHAPTER 3 – RESULTS AND DISCUSSION 
 
3.1. Synthesis of the carbaldehydic xanthone LEM2 
 
LEM2 is synthetic carbaldehydic xanthone which has displayed an inhibitory 
activity of p73:MDM2 interaction in a p53-null human colon carcinoma tumor cell line 
expressing p73 (not p53 and p63)*.  
The previous synthetic pathway in obtaining the carbaldehydic xanthone LEM2, 
described on Scheme 1, consisted of five reaction steps: (1) a Friedel-Crafts acylation 
using aluminum chloride as an acid catalyst; (2) a nucleophilic addition followed by an 
elimination of methanol under basic conditions and microwave heating; (3) a selective 
demethylation of the methoxyl group at position 4 using as a dealkylating agent aluminium 
chloride; (4) a Duff formylation at position 1 using hexamethylenetetramine as a formyl 
group source; (5) a methylation of the phenolic hydroxyl group at position 4 with methyl 
sulfate (unpublished results).  
 
 
Scheme 1 – Different reaction steps of the previous synthesis of carbaldehydic xanthone LEM2. HMTA = 
hexamethylenetetramine; r.t. = room temperature; MW = microwave. 
a 
isolated yields.  
 
* Ramos, H., Leão, M., Soares, J., Raimundo L., Queiroz, G., Brandão, P., Pinto, M., Sousa, E., 
Saraiva, L.”LEM2: a new small-molecule inhibitor of the p73:MDM2 interaction”. Book of Abstracts-8
th
 
Meeting of Young Researchers of University of Porto, 13-15 May 2015, p.165. 
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The high number of reaction steps needed to synthesize the carbaldehydic 
xanthone LEM2 as well as the low overall yield of the process demanded a synthetic 
pathway more appropriate for scale-up with a lower number of reaction steps. The 
alternative synthetic pathway of LEM2 consisted in obtaining the carbaldehyde from an 
appropriate methyl derivative and four reaction steps were needed as will be described 
below.        
  
3.1.1. Synthesis of the benzophenone intermediate 3, (2-hydroxy-3,4-
dimethoxy-6-methylphenyl) methoxyphenyl) methanone 
 
The synthesis of benzophenone intermediates suitable as precursors for 
cyclisation of xanthones is achieved at room temperature by the Friedel-Crafts acylation of 
methoxybenzene derivatives with the properly substituted benzoyl chloride in the 
presence of a Lewis acid, as aluminium chloride (Scheme 2). To obtain benzophenone 
intermediate 3, aluminium chloride anhydrous was added to a dry diethyl ether solution of 
2-methoxybenzoyl chloride (2) and trimethoxytoluene (3). After completing the reaction, 
the suspension was acidified with HCl (5M) to convert the phenolate group of the 
benzophenone derivative to a non-ionized form. Then, the non-ionized form of the 
benzophenone derivative was extracted with chloroform. A brown oil which contains the 
final product was obtained and used without further purification processes to the next 
reaction step.   
 
 
Scheme 2 - Friedel-crafts acylation of trimethoxytoluene (1) with 2-methoxybenzoyl chloride (2) to obtain 
benzophenone intermediate 3. r.t. = room temperature. 
 
3.1.2. Synthesis of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4): cyclization of 
benzophenone intermediate 3 
The benzophenone intermediate 3 contained in the crude product formed in the 
previous reaction was then cyclized to a xanthone intermediate through a reaction that 
involves a nucleophilic addition followed by an elimination of methanol (Scheme 3). 
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Scheme 3 – Cyclization of the benzophenone intermediate 3 to xanthone intermediate 4. MW = microwave. 
 
The cyclization of benzophenone intermediates is time-consuming when performed under 
conventional heating. In this context, the use of microwave heating constituted an 
alternative approach of obtaining the xanthone intermediate 4, demanding lower reaction 
times when compared to conventional heating87. The reaction of cyclization was 
undergone in basic solution, contributing to the deprotonation of acidic phenolic hydroxyl 
group and the subsequent nucleophilic addition. A white solid insoluble in basic solution 
was formed and contained the xanthone intermediate 4. After completing the reaction, the 
solid was trapped by a vacuum filtration. The intermediate 4 contained in solid was 
identified by comparing with a standard sample after crystallization. Since a great amount 
of xanthone intermediate 4 can be lost by crystallization, the impure white solid containing 
the intermediate 4 was used for next reaction step. 
 
3.1.3. Synthesis of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one (5) 
The synthesis of the dibrominated xanthone intermediate 5 can be accomplished 
by a benzylic bromination (Vohl-Ziegler reaction) of xanthone intermediate 4 catalyzed by 
free radicals (Scheme 4). The oxygen-oxygen bond of benzoyl peroxide is weak, and so 
benzoyl peroxide (BPO) can readily undergo homolytic cleavage, forming reactive free 
radicals which act as initiators of the reaction of benzylic bromination. N-
bromosuccinimide (NBS) is a reactant extensively used in these radical reactions as a 
source of bromine radicals88. The reaction was performed under reflux (85°C) using 
carbon tetrachloride as solvent. In the course of reaction, by analysis of TLC plate, an 
intense spot corresponding to the dibrominated xanthone intermediate 5 was forming. At 
the same time, the intensity of the spot corresponding to xanthone intermediate 4 was 
diminishing, which indicated that the starting material in this reaction was being 
consumed. After completing, a vacuum filtration was carried out to trap some non-soluble 
impurities. The dibrominated xanthone intermediate 5 was exclusively found in the mother 
liquor. Based on TLC analysis, it was observed the presence of several spots in mother 
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liquor and so an additional step of purification was required. In this context, a flash column 
chromatography was performed as a strategy of purification of intermediate 5.  
 
 
Scheme 4 – Vohl-Ziegler reaction: synthesis of dibrominated xanthone intermediate 5 from xanthone 
intermediate 4 by a benzylic bromination catalyzed by free radicals. NBS = N-bromosuccinimide; BPO = 
benzoyl peroxide. 
a 
isolated yield. 
 The reaction conditions described in this section were planned for the synthesis of 
the monobrominated derivative instead of dibrominated xanthone intermediate 5, 
according to a previously described procedure89. The high yield of the referred reaction 
(80%) indicated that a dibromination of xanthone intermediate 4 was the preferential 
pathway based on the reaction conditions employed. The identity of products 3-5 were 
confirmed by TLC comparing with standards previously obtained (unpublished results). 
 
3.1.4. Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2) 
 
As in the previous reaction step, a dibrominated intermediate was preferentially 
synthesized, a debromination reaction step was needed to convert the intermediate 5 into 
a monobrominated xanthone derivative to proceed with an oxidation to the carbaldehydic 
xanthone LEM2. On literature, it was found a promising strategy of selective 
debromination promoted by an ionic liquid90. The ionic liquids have been extensively used 
in organic synthesis for last few years. They are classified as green solvents since they 
are non-flammable, non-volatile and recyclable91. However, according to the procedure 
described on literature, there are some considerations that should be taken into account: 
(1) the experimental procedure for selective debromination was employed for α-
dibromoketones and the intermediate 5 is a ɣ-dibromoketone; (2) the reaction was 
performed under conventional heating (100°C) and not under microwave heating; (3) the 
ionic liquid used in this reaction was 1-butyl-3-methylimidazolium tetrafluoroborate 
[(BMIm)BF4], instead of 1-methyl-3-pentylimidazolium tetrafluoroborate [(pmIm)BF4] 
described in literature. In the course of the reaction, an intense spot with a different Rf of 
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the xanthone intermediate 5 was forming, while the spot corresponding to intermediate 5 
was progressively disappearing. After finishing the reaction, the crude material was 
submitted to a liquid-liquid extraction with ethyl acetate in order to remove the ionic liquid 
and the water used in this reaction. A flash column chromatography was performed to 
remove the impurities contained on the crude material. It was hypothesized that the 
intense spot found on TLC plate corresponded to the monobrominated intermediate. 
Surprisingly, structural elucidation techniques have shown that the product formed was 
the carbaldehydic xanthone LEM2. According to these unexpected results, it is 
hypothesized that a solvolytic displacement of the intermediate 5 using water and 
[(BMIm)BF4] was the preferential pathway instead of a debromination pathway
92 (Scheme 
5). 
 
Scheme 5 - Synthesis of carbaldehydic xanthone LEM2 by a solvolytic displacement of dibrominated 
xanthone intermediate 5 using water and ionic liquid as solvents. [(BMIm)BF4] = 1-butyl-3-methylimidazolium 
tetrafluoroborate. 
a
 isolated yield. 
 
3.2. Synthesis of aminoxanthone derivatives 
 
Several strategies to synthesize a library of aminoxanthone derivatives were 
employed using different reaction conditions. Regardless of the different reaction 
conditions used, the aminoxanthone derivatives were obtained by reductive amination of 
the carbaldehydic xanthone LEM2. The general reaction is represented in Scheme 6. 
 
  
Scheme 6 – General reaction of reductive amination of LEM2 with a primary amine.  
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The reductive aminations or reductive alkylations are among the most useful and 
important strategies in the synthesis of different kinds of amines. In fact, reductive 
amination is in the top 10 reactions most used to obtain drug candidates93. The 
aminoxanthone derivatives were synthesized in a one pot conversion resulting from the 
reaction of the carbonyl group of the carbaldehydic xanthone LEM2 with the amines, in 
the presence of a reducing agent. In the mechanistic point of view (Scheme 7), the 
condensation reaction of LEM2 (6) with the amine (7) initiates by a nucleophilic addition of 
the amine group to the electrophilic carbon of the carbonyl group of LEM2, leading to the 
formation of the intermediate hemiaminal, also called carbinolamine (8), which is generally 
unstable and cannot be isolated. The carbinolamine intermediate 8 is then dehydrated by 
protonation of its hydroxyl group to form the intermediate 9, a Schiff base (an imine or an 
enamine, if the reactant is a primary or secondary amine, respectively). Subsequently, the 
intermediate Schiff base is reduced to furnish the alkylated amine product (10). In fact, in 
the presence of a suitable reducing agent, the reaction of LEM2 with a primary amine 
yields a secondary amine, via an imine intermediate and the reaction with a secondary 
amine yields a tertiary amine, via an enamine intermediate94. The reductive amination with 
tertiary amines is not mechanistically possible. 
 
Scheme 7– Mechanism of the reaction of the carbaldehydic xanthone LEM2 (6) with a primary amine (7), via 
an imine intermediate (9), to yield a secondary amine (10), in presence of suitable reducing agents.  
The reductive amination reactions can be described as direct reactions, when a 
carbonylated compound and the amine are mixed with a suitable reducing agent without 
prior formation of the intermediate Schiff base, and indirect reactions, when the reductive 
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amination occurs in two separated steps: the formation of intermediate Schiff base 
followed by reduction to obtain the final product94.  
In case of direct reductive aminations, the choice of a reducing agent is crucial for 
the success of these reactions, because a suitable reducing must reduce the intermediate 
Schiff base selectively over carbonylated compounds. A better understanding of the 
characteristics of the each reducing agent is essential to select the most favorable 
reaction conditions for the synthesis of a library of aminoxanthone derivatives of 
carbaldehydic xanthone LEM2.  
Initially, a solid-supported reactant containing borohydride (MP-BH4) was used 
since previously it was successfully used in our research group to synthesize an 
aminoxanthone derivative (unpublished results). Nevertheless, under the conditions 
described in Scheme 8, the carbaldehydic xanthone LEM2 was not completely consumed 
and the reduction of the carbonyl group to the alcohol derivative of LEM2 (11) was the 
preferential synthetic pathway. In fact, the major product formed in the course of reaction 
was isolated by a column chromatography and spectroscopic techniques have shown that 
the product formed was 1-(hydroxymethyl)-3,4-dimethoxy-9H-xanthen-9-one (11). The 
reaction yield of formation of the alcohol derivative was not determined.  
 
Scheme 8 – Reaction conditions employed for reductive amination of the carbaldehydic xanthone LEM2, 
using MP-BH4 as a reducing agent and methanol as solvent. r.t. = room temperature. 
 
In fact, according to the literature, sodium borohydride (NaBH4) is not suitable for 
direct reductive aminations, since NaBH4 reduces the Schiff base intermediates in the 
same manner that it reduces the carbonyl group of the carbonylated compounds95. For 
that reason, alternative reducing agents need to be used in order to overcome the lack of 
selectivity of NaBH4. The application of the selective sodium cyanoborohydride 
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(NaBH3CN) has emerged as a successful approach, however the toxicity associated to 
the reducing agent limits its use in reductive aminations96. Another selective reducing 
agent, sodium triacetoxyborohydride [NaBH(OAc)3], is selective in direct reductive 
aminations and constitutes an appealing alternative to surmount the toxicity issues of 
NaBH3CN. The replacement of cyano group of NaBH3CN with acetoxy groups of 
NaBH(OAc)3 lead to an increased safety. Structurally, the steric and the electron-
withdrawing effects of the three acetoxy groups stabilize the B-H bond and are 
responsible for its mild reducing properties94. 
 In this context, a different procedure for synthesis of aminoxanthone derivatives 
was employed in order to promote a full consumption of LEM2 and avoid the undesirable 
reduction of the carbonyl group. The reaction conditions described in Scheme 9, using the 
sodium triacetoxyborohydride/tetrahydrofuran system, allowed a total consumption of the 
carbalhdehydic xanthone LEM2, favoring the amination synthetic pathway. 
 
 
 
Scheme 9 – General reaction of reductive amination of the carbaldehydic xanthone LEM2, using STAB as a 
reducing agent and THF as solvent. THF = tetrahydrofuran, r.t. = room temperature, STAB = sodium 
triacetoxyborohydride. 
  
For monitoring the synthesis of aminoxanthone derivatives by TLC, two different 
chromatographic systems were used, one to observe the disappearance of the 
carbaldehydic xanthone LEM2 (n-hexane/ethyl acetate, 7:3) and another to visualize both 
amine precursor and the appearance of the desired product (methanol/TEA, 100:0.1 for 
amines 12-18, chloroform/acetone/TEA, 5:5:0.1 for amines 19-22). The syntheses of each 
derivative were grouped according to the structural similarity of the aminoxanthone 
derivatives: (1) alkylated linear, (2) heterocyclic and (3) halogenated aromatic 
aminoxanthone derivatives. The general work-up of these derivatives is outlined on 
Scheme 10. 
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Scheme 10 – General reaction work-up of the new synthesized aminoxanthone derivatives 12-22. (A) Amines 
12, 13, 15, 19, 20, 21, 22, (B) amines 14, 16, 17, 18; (C) amines 19, 20, 21, 22; (D) amines 12, 13, 15; (E) 
amines 14, 17, 18, 19, 20, 21, 22; (F) amines 12, 13, 14. 
3.2.1. Synthesis of alkylated linear aminoxanthone derivatives 
 
With this procedure described in Scheme 11, three alkylated linear derivatives 
were obtained: 3,4-dimethoxy-1-(((2-morpholinoethyl)amino)methyl)-9H-xanthen-9-one 
(12), 1-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-
one (13) and 1-(((2-(diethylamino)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one 
(14), in 56%, 62%, and 40% yield respectively. 
The alkylated linear aminoxanthone derivatives 12-14 were visualized by UV 
revelation at 254 and 365 nm. By chemical revelation with ninhydrin, only the secondary 
amines 12 and 14 were observed. Similar purification strategies were employed to purify 
the crude material containing each aminoxanthone derivative.  
 The amines 12 and 13 were purified by a liquid-liquid extraction under acidic and 
basic solutions. Initially, the crude material was basified in order to convert the amines to 
their non-ionized form and extracted with chloroform to remove the water-soluble reducing 
agent. An extraction with acid was performed to eliminate the non-basic impurities and the 
non-ionized amines were then recovered by basification and subsequent extraction with 
chloroform. In a different manner, the purification of 14 was carried out by a liquid-liquid 
extraction with water and chloroform. The resulting organic phase was then subjected to a 
solid-phase extraction (SPE) with a cation exchange cartridge to separate the basic 
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amines from the non-basic impurities, as the alcohol derivative 11. According to this 
procedure, the amine 14 and its precursor were trapped on the cartridge due to their 
basicity and the non-basic impurities were eluted first. Then, the desired product was 
removed from the cartridge with extraction with basic solution. However, these two 
different purification approaches revealed to be insufficient for amines 12, 13 and 14 
because the amine precursors were not separated from respective products. In fact, a 
chromatography flash cartridge was performed in order to eliminate the amine precursors 
and obtain pure aminoxanthone derivatives.  
The similarity of reaction yields between aminoxanthones 12 and 13 may reflect 
the same work-up procedures performed for these amines. A lower yield obtained for 
amine 14 may be justified by purification approach applied.   
 
 
Scheme 11 – Synthesis of alkylated linear aminoxanthone derivatives from carbaldehydic xanthone LEM2. 
THF = tetrahydrofuran, r.t. = room temperature. 
a
 isolated yields.  
 
3.2.2. Synthesis of heterocyclic aminoxanthone derivatives  
 
Based on the reaction conditions described in Scheme 12 and the experimental 
procedure, it was obtained four heterocyclic aminoxanthone derivatives: 1-((4-(2-
hydroxyethyl)piperazin-1-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one (15), 4-((3,4-
dimethoxy-9-oxo-9H-xanthen-1-yl)methyl)piperazin-2-one (16), 1-((5-amino-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one (17) and 3,4-
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dimethoxy-1-(piperidine-1-ylmethyl)-9H-xanthen-9-one (18) in 68%, 35%, 36%, and 58% 
respectively. 
The tertiary heterocyclic aminoxanthone derivatives were only identifiable after UV 
revelation at 254 and 365 nm. Despite structural similarities of these heterocyclic 
aminoxanthones, different purification techniques were employed.  
In case of amine 15, a liquid-liquid extraction with acidic and basic solutions was 
carried out in an identical way of amines 12 and 13. After this procedure, it was 
expectable the presence of the impurity corresponding to the amine precursor of 15. 
Surprisingly, chemical revelation by ninhydrin did not identify the secondary amine 
precursor, which indicated that the liquid-liquid extraction was sufficient for a total 
purification of amine 15. Probably, the water solubility of 1-(2-hydroxyethyl)piperazine, the 
amine precursor of 15, allowed a prior elimination in the initial aqueous phase of liquid-
liquid extraction. 
 
Scheme 12 – Synthesis of heterocyclic aminoxanthone derivatives from carbaldehydic xanthone LEM2. THF 
= tetrahydrofuran, r.t. = room temperature. 
a
 isolated yields. 
  
The work-up of amines 17 and 18 consisted of a liquid-liquid extraction with water 
and chloroform to eliminate the water soluble sodium triacetoxyborohydride. In case of 
amine 16, a liquid-liquid extraction with acidic and basic solution could destabilize the 
lactam ring of the aminoxanthone derivative. To avoid the hydrolysis of the lactam ring, 
the crude material was subjected to an identical work-up of 17 and 18. The resulting 
organic phase containing each derivative was further purified by a SPE with a cation 
exchanger cartridge. Particularly, for amine 17, the fractions eluted with basic solution 
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(NH3 2% in methanol) were gathered and the compound was crystallized from the solvent 
mixture. The structure of 17 proposed in Scheme 12 was confirmed by spectroscopic 
techniques. The preferential conjugation with the heterocyclic amine group was 
expectable since an aromatic amine group did not have its non-bonding electron pair 
available to proceed to nucleophilic addition to carbonyl group of LEM2. In case of amines 
16 and 18, the SPE allowed a total purification of these derivatives without any further 
procedures. These evidences were checked by the absence of the secondary amine 
precursors of 16 (2-oxopiperazine) and 18 (piperidine) after ninhydrin revelation. Probably, 
the water solubility of 2-oxopiperazine and piperidine allowed a prior removal from the 
aqueous phase on liquid-liquid extraction.  
3.2.3. Synthesis of halogenated aromatic aminoxanthone derivatives 
Based on the reaction conditions described in Scheme 13 and the experimental 
procedure, four halogenated aromatic aminoxanthone derivatives were obtained: 1-(((4-
fluorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (19), 1-(((4-chlorobenzyl) 
amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (20), 1-(((1-(4-chlorophenyl)ethyl)amino) 
methyl)-3,4-dimethoxy-9H-xanthen-9-one (21) and 1-(((4-bromobenzyl)amino)methyl)-3,4-
dimethoxy-9H-xanthen-9-one (22) in 40%, 57%, 63%, and 70% yield respectively. 
 
Scheme 13 – Synthesis of halogenated aromatic aminoxanthone derivatives from carbaldehydic xanthone 
LEM2. THF = tetrahydrofuran, r.t. = room temperature. 
a
 isolated yields. 
The synthesis of this group of halogenated aromatic aminoxanthones was 
controlled by a chromatographic system (chloroform/acetone/TEA, 5:5:0.1) different from 
 53 
   
the used for the other two groups (methanol/TEA, 100:0.1). The secondary halogenated 
aromatic aminoxanthone derivatives were easily identifiable after UV and chemical 
revelation with ninhydrin. In a similar manner of 12, 13 and 15, the purification strategy 
was based on a liquid-liquid extraction with acidic and basic solutions in order to remove 
the reducing agent and the non-basic impurities present in crude material. Surprisingly, it 
was evidenced that, upon extraction with acid solution, the halogenated aromatic 
aminoxanthones 19, 20, 21 and 22 remained exclusively in the chloroform phase, but their 
amine precursors were easily converted to their ionized-form. Probably, the halogenated 
aromatic aminoxanthones present a lower basicity than the respective amine precursors 
and this difference of basicity allowed an efficient separation of both aminoxanthones and 
amine precursors by using this procedure. However, additional purification techniques 
were employed to separate the non-basic impurities from the halogenated aromatic 
aminoxanthone derivatives contained the chloroform phase. To achieve this goal, a SPE 
with a cation exchange cartridge allowed an initial elimination of the non-basic impurities 
such as the alcohol derivative 11. Then, the aminoxanthone derivatives were eluted with 
basic solution and the pure fractions were gathered.  
 According to the reaction yields, it was observed an increased yield with the 
decrease of electronegativity of the halogen atom. In fact, a higher yield was obtained for 
synthesis of amine 22 and, comparing the electronegativity of halogen atoms, the bromine 
is the least electronegative. The lower electronegativity of the para halogen atom may 
reflect in a lower electron-withdrawing inductive effect and, consequently, in a higher 
availability of the non-bonding electron pair of the amine group to undergo a nucleophilic 
addition to the carbonyl group of the carbaldehydic xanthone LEM2.   
3.3. Strucuture elucidation  
The structure characterization of new synthesized aminoxanthone derivatives as 
well as the alcohol derivative of LEM2, 11, was established for the first time by melting 
points determination, IR, NMR and MS techniques. In this section, it will be presented IR, 
1H and 13C NMR data for the carbaldehydic xanthone LEM2 and their derivatives. 
3.3.1. IR spectroscopy data  
The IR data for carbaldehydic xanthone LEM2 indicates the presence of, a band 
corresponding to the C=O at 1649 cm-1, as well as, bands corresponding to the C=C at 
aromatic bond typical from the xanthone scaffold at 1580, 1464, 1320 and 1132 cm-1. An 
additional band corresponding to the aldehydic C=O bond at 1684 cm-1 was observed in 
IR spectrum. For the alcohol derivative 11 and the aminoxanthone derivatives 12-22, a 
similarity of IR spectrum profile was observed when compared to LEM2 (Table 3). 
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Table 3 - IR data for LEM2 and derivatives 11-22. 
Compounds Group  (cm-1) 
 
 
 
  
                         LEM2 
C-H 2927 
Aldehydic C=O 1684 
C=O 1649 
C=C (Ar) 1580, 1464, 1320, 1132 
 
 
 
 
11 
O-H 3460 
C-H 2938 
C=O 1618 
C-C (Ar) 1584, 1466, 1327, 1130 
 
 
 
 
12 
N-H 3303 
C-H 2925, 2853 
C=O 1615 
C-N 1257 
C-C (Ar) 1470, 1328, 1146 
 
 
13 
C-H 2938, 2785 
C=O 1615 
C-N 1259 
C-C (Ar) 1464, 1346, 1154 
 
 
14 
N-H 3316 
C-H 2940, 2841 
C=O 1615 
C-N 1258 
C-C (Ar) 1585, 1467, 1312, 1131 
 
 
 
15 
O-H 3423 
C-H 2932, 2804 
C=O 1617 
C-N 1256 
C-C (Ar) 1586, 1466, 1345, 1160 
 
 
 
16 
N-H (amide) 3280 
C-H 2923, 2852 
C=O (amide) 1675 
C=O 1617 
C-N 1259 
C-C (Ar) 1585, 1465, 1379, 1129 
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(continuing) 
Compounds Group  (cm-1) 
 
 
17 
N-H (aromatic) 3387 
C-H 2927, 2866 
C=O 1617 
C-N 1257 
C-C (Ar) 1466, 1343, 1130 
 
 
18 
C-H 2929, 2853 
C=O 1618 
C-N 1257 
C-C (Ar) 1585, 1467, 1346, 1131 
 
 
 
19 
N-H 3322 
C-H 2921, 2853 
C=O 1614 
C-N 1260 
C-C (Ar) 1584, 1467, 1193, 1132 
 
 
20 
N-H 3315 
C-H 2919, 2847 
C=O 1615 
C-N 1258 
C-C (Ar) 1499, 1464, 1317, 1150 
 
 
21 
N-H 3310 
C-H 2936, 2730 
C=O 1616 
C-N 1260 
C-C (Ar) 1496, 1466, 1347, 1132 
 
 
22 
N-H 3317 
C-H 2919, 2850 
C=O 1613 
C-N 1256 
C-C (Ar) 1467, 1329, 1132 
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Comparing the IR spectrum of 11 with LEM2, the detection of a new band at 3460 
cm-1 corresponding to a O-H bond in amine 11 spectrum and not the band corresponding 
to the aldehydic C=O of LEM2 bond put in evidence the hypothesized transformation. In 
this case, the IR data confirmed that the formyl group of LEM2 was reduced to a hydroxyl 
group. Since the different aminoxanthones were synthesized by conjugation of the amines 
with the formyl group of LEM2, it was expectable some differences on the IR spectrum 
profile as a consequence of the conversion of the carbonyl group of the carbaldehyde to 
an amine derivative. In fact, according to data provided by Table 3, the band 
characteristic of aldehydic C=O group is only present in LEM2 spectrum and the detection 
of new bands characteristic of a C-N bond (and N-H bond for secondary aminoxanthone 
derivatives) evidenced for all aminoxanthones indicated that the reductive amination of the 
formyl group of LEM2 was successfully accomplished. 
 
3.3.2. Carbaldehydic xanthone LEM2 and alcohol derivative 11 
 
3.3.2.1. 1H NMR for LEM2 and alcohol derivative 11 
The data corresponding to the 1H NMR of LEM2 and amine 11 is represented in 
Table 4.  
Table 4 - 1H NMR data* for LEM2 and alcohol derivative 11. 
 
 
 
 
LEM2 
 
11 
 
Protons  δH  δH 
H-1’ 11.21, 1H, s 4.95, 2H, s 
H-8 8.31, 1H, dd, J=8.0 and 1.7 8.32, 1H, dd, J=8.0 and 1.7 
H-6 7.77, 1H, ddd, J=8.5, 7.0 and 1.7 7.75, 1H, ddd, J=8.5, 7.0 and 1.7 
H-5 7.60, 1H, dd, J=8.5 and 0.8 7.56, 1H, dd, J=8.5 and 0.9 
H-2 7.56, 1H, s 6.98, 1H, s 
H-7 7.43, 1H, ddd, J=8.0, 7.0 and 0.8 7.41, 1H, ddd, J=8.0, 7.0 and 0.9 
H-4 4.11, 3H, s 4.04, 3H, s 
H-3 4.07, 3H, s 4.02, 3H, s 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz.  
 
The 1H NMR spectrum of LEM2 shows the presence of five signals corresponding 
to the five aromatic protons, namely H-2, H-5, H-6, H-7, and H-8 (δH 7.43-8.31 ppm). The 
aromatic protons most deshielded are the protons H-6 and H-8. The electron-withdrawing 
 57 
   
effect of carbonyl group (C-9) for resonance contributes to an electronic deprotection of 
orto (H-8) and para (H-6) positions of the aromatic ring. The magnetic anisotropy of 
carbonyl group (C-9) deshields preferentially the proton H-8, which explains the higher 
chemical shift of proton H-8 in relation to H-6. The signal with the highest chemical shift 
value corresponds to the aldehydic proton H-1’ (δH =11.21 ppm) due to magnetic 
anisotropy and electron-withdrawing effects of the carbonyl group of the carbaldehyde. 
The protons corresponding to the methoxyl groups (H-3 and H-4) are equivalent for each 
methoxyl group. In spite of their similarity, the protons H-4 present a slightly higher 
chemical shift than the protons H-3. This evidence was confirmed by heteronuclear single 
quantum correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) 
techniques. 
Analysing the 1H NMR spectrum of 11, the multiplicity and coupling constants of 
the four aromatic protons (H-5, H-6, H-7, and H-8) of the aromatic region of the xanthone 
scaffold (δH ranging from 7.41 to 8.32 ppm) as well as the six protons of the methoxyl 
group (δH-3 4.02 ppm; δH-4 4.04 ppm) were similar to LEM2. However, a decrease in 
chemical shift value for aromatic proton H-2 of 11 was observed. In the carbaldehydic 
xanthone LEM2, the aromatic proton H-2 is subjected to the deshielding effect of orto 
formyl group. The conversion of the carbonyl group to hydroxyl group contributes to the 
elimination of the deshielding effect at orto position. Also, the absence of signal 
corresponding to the carbonyl group of LEM2 and the appearance of a singlet 
corresponding to the methylene group (-CH2-) was evidenced on 
1H NMR spectrum (δH 
4.95 ppm).  This evidence confirmed the reduction of the carbaldehydic xanthone LEM2.  
 
3.3.2.2. 13C NMR for LEM2 and alcohol derivative 11 
The data corresponding to the 13C NMR of LEM2 and amine 11 is represented in 
Table 5.  
The 13C NMR spectrum for LEM2 revealed the presence of two signals with the 
highest chemical shifts corresponding to the carbons of carbonyl groups (δC-9=177.9 ppm; 
δC-1’=192.8 ppm). It is also possible the visualization of signals corresponding to the 
carbons of the xanthone scaffold (values of δC between 108 and 156 ppm, corresponding 
to the remaining twelve carbons. The two carbons corresponding to the methoxyl groups 
present the lowest chemical shifts. 
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Table 5 – 13C NMR data* for LEM2 and alcohol derivative 11 
 
 
 
 
LEM2 
 
11 
 
Carbons   δC  δC 
C-1’ 192.8 65.7 
C-9 177.9 179.0 
C-3 156.3 156.7 
C-10a 155.5 155.4 
C-4a 150.9 152.3 
C-4 140.7 136.1 
C-6 135.1 134.9 
C-1 133.5 139.3 
C-8 126.7 126.7 
C-7 124.5 124.2 
C-8a 121.9 121.9 
C-5 117.8 117.7 
C-9a 116.1 114.8 
C-2 108.5 110.3 
C-4’’ 61.8 61.6 
C-3’’ 56.6 56.4 
*Values in ppm (δC) relative to (CH3)4Si as an internal reference. 
 
For LEM2, 13C NMR assignments of the hydrogenated carbons were determined 
by HSQC and the carbon atoms not directly bonded to hydrogen atoms were deduced by 
HMBC experiments. The data provided by HMBC spectrum confirmed the structure of the 
carbaldehydic xanthone LEM2 (Figure 13). 
 
Figure 13 – Correlations detected in HMBC spectrum for compound LEM2. 
 
The 13C NMR spectrum of 11 exhibited a similar profile of the respective precursor. 
In fact, the chemical shifts of the thirteen carbon atoms of the xanthone scaffold and the 
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two carbons of the methoxyl groups of 11 are almost equivalent. However, the carbon 1 in 
11 presented a higher chemical shift value (δC-1 139.3 ppm) than in LEM2 (δC-1 133.5 
ppm). Also, the appearance of a signal corresponding to the carbon of methylene group 
(δC-1’ 65.7 ppm) evidenced that the conjugation between the starting material and the 
amine building block occurred.  
 
3.3.3. Alkylated linear aminoxanthone derivatives: 12, 13, and 14 
3.3.3.1. 1H NMR for amines 12, 13, and 14 
The 1H NMR spectra of alkylated linear aminoxanthone derivatives (Table 6) 
displayed signals with similar chemical shifts of precursor LEM2 corresponding to the 
aromatic protons H-5, H-6, H-7, and H-8 (δH values between 7.4 and 8.3 ppm) and to the 
six protons of the methoxyl groups H-3 and H-4 (δH values ranging from 4.0 to 4.1 ppm). 
For 12 and 14, it was observed a decrease in chemical shift value for aromatic proton H-2 
(12: δH-2 7.09 ppm; 14: δH-2 7.14 ppm). 
Table 6 - 1H NMR data* for amines 12, 13, and 14.  
 
 
 
 
 
12 13 
 
14 
Protons  δH  δH δH 
H-8 8.25, 1H, dd, J=8.0 and 1.6 8.25, 1H, dd, J=8.0 and 1.6 8.27, 1H, dd, J=8.0 and 1.6 
H-6 7.72, 1H, ddd, J=8.4, 7.0 and 
1.6 
7.69, 1H, ddd, J=8.5, 7.0 and 
1.6 
7.71, 1H, ddd, J=8.5, 7.0 
and 1.6 
H-5 7.57, 1H, dd, J=8.4, 0.9 7.54, 1H, dd, J=8.5 and 0.9 7.56, 1H, dd, J=8.5 and 0.9 
H-7 7.38, 1H, ddd, J= 8.0, 7.0 and 
0.9 
7.35, 1H, ddd, J=8.0, 7.0 and 
0.9 
7.37, 1H, ddd, J=8.0, 7.0 
and 0.9  
H-2 7.09, 1H, s 7.53, 1H, s 7.14, 1H, s 
H-1’ 4.34, 2H, s 4.36, 2H, s 4.39, 2H, s 
H-4 4.04, 3H, s 4.05, 3H, s 4.05, 3H. s 
H-3 4.01, 3H, s 4.02, 3H, s 4.01, 3H, s 
H-5’ 3.66, 4H, t, J= 4.6 2.44, 2H, t, J=7.3 1.01, 6H, t, J=7.1 
H-2’ 2.90, 2H, t, J= 6.1 2.39, 3H, s 2.87, 2H, t, J=6.4 
H-3’ 2.60, 2H, t, J= 6.1 2.65, 2H, t, J=7.3 2.68, 2H, t, J=6.4 
H-4’ 2.47, 4H, t, J= 4.6 1.82, 2H, q, J=7.3 2.55, 4H, q, J=7.1 
H-6’ - 2.28, 6H, s - 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz.  
 
Overall, the absence of the signal corresponding to an aldehydic proton and the 
presence of a singlet corresponding to the two protons H-1’ of methylene group (-CH2-) 
 60 
 
evidences the successful reductive amination of LEM2 with the respective amine 
precursors.  
The methylene groups appear at δH 4.34 (s, CH2) ppm for 12, δH 4.36 (s, CH2) ppm 
for 13 and δH 4.39 (s, CH2) ppm for 14. The signal corresponding to the N-H group was 
not observed for the secondary amines 12 and 14.  
 
3.3.3.2. 13C NMR for amines 12, 13, and 14 
 
The 13C NMR spectra for compounds 12, 13, and 14 (Table 7) displayed signals 
corresponding to the carbons atoms of the carbonyl group (C-9), the two aromatic rings 
(δC ranging from 110 to 157 ppm), the two methoxyl groups at position 3’’ and 4’’ and the 
carbon atoms of the aminated chain.  
 
Table 7 – 13C NMR data* for amines 12, 13, and 14.  
 
 
 
 
 
12 
 
13 
 
 
 
14 
Carbons   δC  δC δC 
C-9 178.0 178.1 178.1 
C-3 156.5 156.6 156.5 
C-10a 155.3 155.2 155.3 
C-4a 152.1 151.9 152.1 
C-4 137.0 136.7 137.4 
C-1 136.0 135.0 135.8 
C-6 134.6 134.2 134.5 
C-8 126.5 126.6 126.6 
C-7 124.1 123.9 124.0 
C-8a 122.1 122.4 122.2 
C-5 117.7 117.6 117.7 
C-9a 114.6 114.5 114.5 
C-2 111.6 109.0 111.1 
C-5’ 67.0 57.8 11.6 
C-4’’ 61.5 61.5 61.5 
C-2’ 57.4 42.5 46.8 
C-3’’ 56.4 56.4 56.4 
C-1’ 53.7 60.1 52.4 
C-4’ 53.5 25.3 46.9 
C-3’ 45.3 56.1 53.4 
*Values in ppm (δC) relative to (CH3)4Si as an internal reference.  
 
The presence of a signal corresponding to the carbon atom of the methylene group 
(-CH2-) that appear at δC 53.7 ppm for 12, at δC 60.1 ppm for 13, and at δC 52.4 ppm for 
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14 puts in evidence the successful coupling of the carbaldehydic xanthone LEM2 with 
each amine precursor. The remaining signals corresponding to the carbons of the amine 
moiety presented lower chemical shifts when compared to the carbons of the xanthone 
scaffold (δC ranging from 45.3 to 67.0 ppm for 12, δC ranging from 25.3 to 57.8 ppm for 13, 
and δC ranging from 11.6 to 53.4 ppm for 14).   
 
3.3.4. Heterocyclic aminoxanthone derivatives: 15, 16, 17, and 18 
 
3.3.4.1. 1H NMR for amines 15, 16, 17, and 18 
 
The data corresponding to the 1H NMR of amines 15, 16, 17, and 18 is 
represented in Table 8 and Table 9.  
Table 8 - 1H NMR data* for amines 15 and 16. 
 
 
 
 
 
 
 
 
15 
 
 
 
 
16 
Protons  δH  δH 
H-8 8.25, 1H, dd, J=8.0 and 1.6 8.13, 1H, dd, J=8.0 and 1.6 
H-6 7.68, 1H, ddd, J=8.5, 7.0 and 1.6 7.82, 1H, ddd, J=8.5, 7.0 and 1.6 
H-5 7.53, 1H, dd, J=8.5 and 0.9 7.65, 1H, dd, J=8.5 and 0.8 
H-2 7.48, 1H, s 7.36, 1H, s 
H-7 7.35, 1H, ddd, J=8.0, 7.0 and 0.9 7.45, 1H, ddd, J=8.0, 7.0 and 0.8 
H-1’ 4.32, 2H, s 4.24, 2H, s 
H-4 4.03, 3H, s 3.98, 3H, s 
H-3 4.01, 3H, s 3.90, 3H, s 
H-5’ 3.63, 2H, t, J=5.4 - 
H-2’ 2.68, 4H, m 3.13, 2H, s 
H-3’ 2.63, 4H, m 3.20, 2H, t, J=5.3 
H-4’ 2.58, 2H, t, J=5.4 2.66, 2H, t, J=5.3 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz. 
 
The 1H NMR spectra of heterocyclic aminoxanthone derivatives exhibited the 
presence of signals with identical chemical shifts of precursor LEM2 which corresponded 
to the five aromatic protons H-2, H-5, H-6, H-7, and H-8 (δH values between 7.3 and 8.3) 
of the xanthone scaffold and to the six protons of the methoxyl groups H-3 and H-4 (δH 
values ranging from 3.9 to 4.1 ppm).  
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Table 9 - 1H NMR data* for amines 17 and 18. 
 
 
 
17 
 
 
 
18 
Protons  δH  δH 
H-8 8.26, 1H, dd, J=8.0 and 1.5 8.25, 1H, dd, J=8.0 and 1.6 
H-6 7.69, 1H, ddd, J=8.5, 7.0 and 1.5 7.66, 1H, ddd, J=8.5, 7.1 and 1.6 
H-2 7.57, 1H, s 7.56, 1H, s 
H-5 7.54, 1H, dd, J=8.5 and 0.9 7.57, 1H, dd, J=8.5 and 0.8 
H-7 7.35, 1H, ddd, J=8.0, 7.0 and 0.9 7.33, 1H, ddd, J=8.0, 7.1 and 0.8 
H-6’ 6.99, 1H, t, J=7.7 - 
H-7’ 6.57, 1H, d, J=7.7 - 
H-5’ 6.53, 1H, d, J=7.7 - 
H-1’ 4.48, 2H, s 4.26, 2H, s 
H-4 4.02, 3H, s 4.03, 3H, s 
H-3 3.97, 3H, s 4.01, 3H, s 
H-3’ 3.81, 2H, s 1.65, 4H, q, J=5.3 
H-2’ 2.93, 2H, t, J=6.0 2.57, 4H, t, J=5.3 
H-4’ 2.66, 2H, t, J=6.0 1.50, 2H, q, J=5.3 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz. 
As expectable, the absence of signal of an aldehydic proton and the presence of a 
singlet of the two protons H-1’ of the methylene group (-CH2) evidenced the success of 
the synthesis of these derivatives by reductive amination on formyl group of LEM2. The 
methylene group appears at δH 4.32 (s, CH2) ppm for 15, δH 4.24 (s, CH2) ppm for 16, δH 
4.48 (s, CH2) ppm for 17, and δH 4.26 (s, CH2) ppm for 18. The remaining signals 
characteristic of the protons of the four aminated chains were observed at lower chemical 
shifts. The signals corresponding to aromatic amine group of 17 (-NH2) and the N-H group 
of the lactam ring of 16 were not observed in the 1H NMR spectra. 
 
3.3.4.2. 13C NMR for amines 15, 16, 17, and 18 
 
The 13C NMR spectra for compounds 15, 16, 17, and 18 (Table 10 and Table 11) 
revealed the presence of signals corresponding to the carbons atoms of the carbonyl 
group (C-9), the two aromatic rings (δC values ranging from 108 to 157 ppm) and the two 
methoxyl groups at position 3’’ and 4’’ (δC values between 56 and 62 ppm).  
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Table 10 - 13C NMR data* for amines 15 and 16. 
 
 
 
 
 
15 
 
16 
Carbons  δC  δC 
C-9 178.1 176.7 
C-3 156.5 156.2 
C-10a 155.2 154.6 
C-4a 152.0 151.8 
C-4 138.8 136.9 
C-1 134.8 135.0 
C-6 134.2 134.7 
C-8 126.6 126.1 
C-7 123.9 124.3 
C-8a 122.5 121.8 
C-5 117.5 117.7 
C-9a 114.6 113.7 
C-2 108.2 109.2 
C-4’’ 61.5 60.9 
C-1’ 60.2 58.5 
C-5’ 59.3 30.7 
C-4’ 57.7 168.0 
C-3’’ 56.2 56.3 
C-3’ 53.5 48.7 
C-2’ 53.2 57.2 
*Values in ppm (δC) relative to (CH3)4Si as an internal reference.  
 
The signal appearing at δC 168.00 ppm corresponded to the downfield carbonyl 
group of the lactam ring of 16. According to the 13C NMR spectrum of 17, the aromatic 
region displayed the presence of six additional signals characteristic of the six aromatic 
carbons of the tetrahydroisoquinolin ring. The carbon C-8’ directly linked to the 
electronegative nitrogen atom of aromatic amine group exhibited the highest chemical 
shift value (δC-8’ 144.1 ppm) followed by the carbons C-5’ and C-9’ (δC-5’ 136.3 ppm; δC-5’ 
126.4 ppm) in meta position. In a similar manner of 1H NMR spectra, the absence of the 
signal corresponded to the carbon of formyl group (-CHO) and the presence of a signal 
characteristic of the carbon atom of the methylene group (-CH2-) confirmed the 
conjugation of the carbaldehydic xanthone LEM2 with each amine precursor. The 
methylene groups appear at δC 60.2 ppm for 15, at δC 58.5 ppm for 16, at δC 60.1 ppm for 
17 and at δC 54.3 ppm for 18. The remaining upfield signals corresponded to non-aromatic 
carbons of the aminated chain (δC values ranging from 53.2 to 59.3 ppm for 15, from 30.7 
to 57.2 ppm for 16, from 24.9 to 56.7 ppm for 17, and from 23.8 to 55.7 ppm for 18).   
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Table 11 - 13C NMR data* for amines 17 and 18. 
 
 
 
17 
 
 
 
 
18 
Carbons  δC  δC 
C-9 178.2 177.5 
C-3 156.7 156.1 
C-10a 155.2 154.7 
C-4a 151.9 151.3 
C-8’ 144.1 - 
C-1 139.3 134.2 
C-5’ 136.3 - 
C-4 134.8 138.9 
C-6 134.2 133.8 
C-8 126.6 126.0 
C-9’ 126.4 - 
C-7 123.8 123.3 
C-8a 122.5 121.9 
C-6’ 119.5 - 
C-5 117.6 117.1 
C-7’ 117.1 - 
C-9a 114.5 113.9 
C-10’ 112.7 - 
C-2 108.0 107.8 
C-4’’ 61.5 60.8 
C-1’ 60.1 54.3 
C-3’ 56.7 25.7 
C-3’’ 56.3 56.1 
C-2’ 51.0 55.7 
C-4’ 24.9  
*Values in ppm (δC) relative to (CH3)4Si as an internal reference.  
 
In case of aminoxanthone 17, the respective amine precursor presents two 
potential sites for conjugation with LEM2: the heterocyclic and the aromatic amine group. 
The assignments of chemical shifts of carbon atoms by HSQC and HMBC confirmed the 
selective conjugation of LEM2 with the heterocyclic amine group of the amine precursor of 
17 (Figure 14). 
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Figure 14 – Correlations between carbons and protons in HMBC spectrum of 17. 
 
3.3.5. Halogenated aromatic aminoxanthone derivatives: 19, 20, 21, and 22 
 
3.3.5.1. 1H NMR for amines 19, 20, 21, and 22 
 
The data corresponding to the 1H NMR of amines 19, 20, 21, and 22 are represented 
in Table 12 and Table 13. 
The 1H NMR spectra of halogenated aromatic aminoxanthone derivatives 19, 20, 
21, and 22 exhibited a similarity to the respective starting material, LEM2, particularly in 
the chemical shifts of the signals corresponded to the four aromatic protons H-5, H-6, H-7 
and H-8 (δH values between 7.4 and 8.3 ppm) of the xanthone scaffold and to the six 
protons of the methoxyl groups H-3 and H-4 (δH values ranging from 4.0 to 4.1 ppm). The 
spectrum also revealed the presence of two additional signals that correspond to the four 
aromatic protons of the aminated chain. The occurrence of the reductive amination of 
LEM2 with each amine precursor was evidenced by the presence of a singlet 
characteristic of the two protons H-1’ of the methylene group (-CH2-) of aminoxanthones. 
In fact, the methylene group appears at δH 4.30 (s, CH2) ppm for 19, δH 4.33 (s, CH2) ppm 
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for 20, δH 4.27 (s, CH2) ppm for 21, and δH 4.31 (s, CH2) ppm for 22, The remaining 
upfield protons are characteristic of each of the four aminated chains. In the case of these 
secondary halogenated amines, the signal corresponding to the N-H was not observed in 
the spectra. 
Table 12 - 1H NMR data* for amines 19 and 20. 
 
 
 
 
19 
 
20 
Protons  δH  δH 
H-8 8.28, 1H, dd, J=8.0 and 1.6 8.25, 1H, dd, J=8.0 and 1.6 
H-6 7.71, 1H, ddd, J=8.5, 7.0 and 1.6 7.79, 1H, ddd, J=8.6, 7.0 and 1.6 
H-5 7.55, 1H, dd, J=8.5 and 0.8 7.60, 1H, dd, J=8.5 and 0.9 
H-7 7.40, 1H, ddd, J=8.0, 7.0 and 0.8 7.43, 1H, ddd, J=8.0, 7.0 and 0.9 
H-4’ 7.36, 2H, m 7.66, 2H, m 
H-3’ 7.01, 2H, m 7.38, 2H, m 
H-2 6.96, 1H, s 7.39, 1H, s 
H-1’ 4.30, 2H, s 4.33, 2H, s 
H-4 4.01, 3H, s 4.07, 3H, s 
H-3 4.01, 3H, s 4.01, 3H, s 
H-2’ 3.85, 2H, s 4.53, 2H, s 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz. 
 
Table 13 - 1H NMR data* for amines 21 and 22. 
 
 
 
 
21 
 
 
 
 
 
22 
Protons  δH  δH 
H-8 8.26, 1H, dd, J=8.0 and 1.6 8.27, 1H, dd, J=8.0 and 1.6 
H-6 7.79, 1H, ddd, J=8.5, 7.0 and 1.6 7.73, 1H, ddd, J=8.5, 7.0 and 1.6 
H-5’ 7.70, 2H, m - 
H-5 7.59, 1H, dd, J=8.5 and 0.8 7.58, 1H, dd, J=8.5 and 0.8 
H-7 7.43, 1H, ddd, J=8.0, 7.0 and 0.8 7.38, 1H, ddd, J=8.0, 7.1 and 0.8 
H-4’ 7.42, 2H, m 7.48, 2H, m 
H-2 7.25, 1H, s 7.08, 1H, s 
H-2’ 4.54, 1H, q, J=6.8 3.88, 2H, s 
H-1’ 4.27, 2H, s 4.31, 2H, s 
H-4 4.04, 3H, s 4.01, 3H, s 
H-3 4.01, 3H, s 4.01, 3H, s 
H-3’ 1.83, 3H, d, J=6.8 - 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference. J values are in Hz. 
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3.3.5.2. 13C NMR for amines 19, 20, 21, and 22 
The 13C NMR spectra for compounds 19, 20, 21, and 22 revealed the presence of 
signals corresponding to the carbons atoms of the carbonyl group (C-9), the two aromatic 
rings (δC values ranging from 111 to 157 ppm) and the two methoxyl groups at position 3’’ 
and 4’’ (δC values between 56 and 62 ppm) (Table 14 and Table 15).  
 
Table 14 - 13C NMR data* for amines 19 and 20. 
 
 
 
  
19 
 
20 
Carbons   δC  δC 
C-9 178.1 179.6 
C-6’ 160.3 127.3 
C-3 156.3 157.0 
C-10a 155.3 155.5 
C-4a 152.2 152.0 
C-4 138.6 137.7 
C-3’ 135.9 129.4 
C-1 135.7 135.8 
C-6 134.5 135.6 
C-5’ 129.8 131.7 
C-8 126.7 126.6 
C-7 124.0 124.6 
C-8a 122.2 121.3 
C-5 117.7 117.9 
C-4’ 115.3 129.5 
C-9a 114.7 114.8 
C-2 110.9 115.5 
C-4’’ 61.5 61.6 
C-3’’ 56.3 57.1 
C-1’ 53.3 51.3 
C-2’ 52.5 50.7 
*Values in ppm (δC) relative to Me4Si as an internal reference. 
In the aromatic region of these four aminoxanthone derivatives, it was evidenced 
the presence of four additional signals corresponding to the six aromatic carbons of the 
halogenated aromatic amine precursor. The carbons positioned orto are subjected a 
higher deshielding effect in relation to meta carbons due to the inductive electron-
withdrawing effect of the halogen atom. Also, NMR data of these derivatives revealed an 
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increase of the chemical shift value of the carbon directly linked to halogen atom with the 
increase of the electronegativity of the halogen.  
In a similar manner of 1H NMR spectra, a signal corresponding to the carbon of 
formyl group (-CHO) was not detected and the presence of a signal characteristic of the 
carbon atom of the methylene group (-CH2-) confirmed the success of the reductive 
amination. The methylene groups appear at δC 53.3 ppm for 19, at δC 51.3 ppm for 20, at 
δC 50.2 ppm for 21, and at δC 52.7 ppm for 22. The remaining signals corresponded to 
non-aromatic carbons of the aminated chain. 
 
Table 15 - 13C NMR data* for amines 21 and 22. 
 
 
 
 
21 
 
22 
Carbons   δC  δC 
C-9 179.6 178.6 
C-3 156.8 156.5 
C-10a 155.4 155.3 
C-4a 151.9 152.2 
C-4 137.6 136.4 
C-6 135.5 134.9 
C-1 134.5 136.2 
C-7’ 131.8 - 
C-6’ 129.8 121.8 
C-5’ 129.5 131.8 
C-4’ 127.3 130.7 
C-8 126.6 126.6 
C-7 124.6 124.2 
C-8a 121.3 121.9 
C-5 117.9 117.7 
C-2 115.6 112.5 
C-9a 114.9 114.7 
C-4’’ 61.6 61.6 
C-2’ 58.9 52.0 
C-3’’ 57.0 56.7 
C-1’ 50.2 52.7 
C-3’ 20.2 128.4 
*Values in ppm (δC) relative to (CH3)4Si as an internal reference.  
 
The derivative 22 was structurally elucidated by HQSC to identify the chemical 
shifts of hydrogenated carbons and by HMBC to deduce to chemical shifts of carbon 
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atoms not directly bonded to hydrogen atoms. The proposed structure corresponding to 
the derivative 22 (Figure 15) was confirmed by HMBC spectrum. 
 
Figure 15 – Correlations between carbons and protons in HMBC spectrum of 22. 
 
Summarized NMR data of the xanthone scaffold representing of aminated 
derivatives 12-22 is represented in Figure 16. According to the data provided by 1H NMR 
and 13C NMR spectra, the chemical shifts of the protons and carbons of the xanthone 
scaffold of the aminoxanthones were not significantly different.  
 
Figure 16 – General structure elucidation of the xanthone scaffold of the aminoxanthone derivatives by 
proton and carbon NMR chemical shifts (ppm) 
 
3.4. Docking simulation studies 
 
The need for a rapid search for small molecules that may interact to targets of 
biological interest is crucial in the drug discovery process37. Computational methods such 
as virtual screening constitute a promising approach for identification of hit compounds, 
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playing an important role in drug discovery research97. Virtual screening, also called in 
silico screening, is a detailed compound database searching approach that allows the 
discovery of new promising scaffolds and small-molecules with a required biological 
activity98. This method involves the rapid computational screening of large libraries of 
chemical structures in order to identify those structures which are most likely to bind to a 
therapeutic target99. Therefore, virtual screening represents a fast and effective tool to 
search for novel lead compounds. 
Depending on the information obtained about the three-dimensional structure of 
therapeutic target, virtual screening can be divided into two approaches: ligand based 
virtual screening, when information about biological target is not available, and structure 
based virtual screening, if the three dimensional structure of target is known. If the 
structure of the biological target is not available, but there are known active ligands, they 
can be used to build a pharmacophore or a three dimensional quantitative structure-
activity relationship (QSAR) study59. Another approach consists in the application of 
techniques of protein structure prediction (homology modeling) to build a structurally 
homologous model of the biological target. When the three-dimensional structure of the 
biological target is known by experimental techniques such as X-ray crystallography, a 
library of virtual ligands is docked against a biological target in order to predict their 
binding affinity100.     
The virtual screening of large libraries of compounds against a target in search of 
novel promising scaffolds is useful approach for Medicinal Chemistry. 
In case of the biological interaction between p53 and MDM2, a structure based 
virtual screening was performed since the three-dimensional structure of the p53:MDM2 
interface is known. 
To predict the inhibitory activity of newly synthesized aminoxanthone derivatives 
against MDM2 protein, docking simulation studies were performed using MDM2 protein 
(PDB code 1YCR). 
The virtual screening of a library of new aminoxanthone derivatives described in 
this dissertation and other obtained in-house compounds derived from three distinct 
building blocks (LEM2, LEM3, and PEX) (Figure 17) resulted in a list of potential MDM2 
ligands, ranked according to their binding affinity to the target. Docking simulation studies 
carried out in PyRx/AutoDock Vina produced nine conformations for each ligand. From the 
total number of 27 compounds screened, four small-molecule inhibitors of p53:MDM2 
interaction (nutlin-3a, α-mangostin, gambogic acid, and pyranoxanthone LEM1) were 
used in the docking studies as positive controls.    
 71 
   
   
Figure 17 – Distinct xanthonic building blocks of the library of aminoxanthone derivatives used in the docking 
studies.   
 
 MDM2 residues Gly58, Asp68, Val75 and Cys77 are described as being critical for 
interaction with p53101. Therefore, docking calculations were restricted to the MDM2 
binding site that contains those residues by building grid box centered on that binding site 
(Figure 18).   
 
Figure 18 – Vina search space (grid box) dimensions and positions in MDM2 (PDB code: 1YCR) in 
PyRx/AutoDock Vina. 
 
 The binding free energies for the best scoring conformations are summarized in 
Table 16. The binding energy values found for known inhibitors of p53:MDM2 interaction, 
which are known to interact with MDM2, were -7.8 kcal.mol-1 for nutlin-3a, -7.7 kcal.mol-1 
for LEM1 and gambogic acid, -6.6 kcal.mol-1 for α-mangostin, and -5.6 kcal.mol-1 for the 
inhibitor of p73:MDM2 interaction, LEM2. The remaining 22 xanthone derivatives 
exhibited binding energy values in this range with the molecule PPX4 displaying the 
highest binding affinity, and therefore, the lowest binding free energy (-7.9 kcal.mol-1) 
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Table 16 – Results of docking simulations for MDM2 (with grid box) performed in 
PyRx/AutoDock Vina. 
 
Ligand 
 
Binding Energy 
(kcal mol-1) 
 
Ligand 
 
Binding Energy 
(kcal mol-1) 
PPX4 -7.9 12 -6.7 
Nutlin-3a -7.8 PPX3 -6.7 
Gambogic acid -7.7 α-Mangostin -6.6 
LEM1 -7.7 14 -6.5 
17 -7.6 15 -6.5 
19 -7.6 PEX1 -6.3 
20 -7.6 PEX3 -6.3 
22 -7.3 13 -6.0 
21 -7.2 PEX -6.0 
PPX2 -7.1 11 -5.9 
18 -7.0 LEM2 -5.9 
16 -6.9 LEM3 -5.7 
PEX2 -6.9 PPX1 -5.2 
PEX4 -6.8 
 
Analysing the docking score values, it was observed that the aminoxanthone 
derivatives presented a higher binding affinity (higher absolute binding energy value) than 
the respective xanthonic building blocks. This observation was expectable since the 
conversion of a formyl group to a bulky amine substituent may contribute to the 
establishment of additional interactions in the binding site of MDM2, resulting in an 
increased binding affinity.  
Nevertheless, concerning the aminoxanthones obtained, all of these derivatives 
showed lower binding affinities (lower absolute binding energy value) than the described 
p53:MDM2 inhibitors LEM1, gambogic acid and nutlin-3a.  
Subsequently, a visual inspection of the LEM2 derivatives and the best ligand 
PPX4 docked onto MDM2 binding site was performed. As shown on Figures 19, 20 and 
21 the best fitting molecule PPX4 and the LEM2 derivatives 11-22 adopted a pose within 
the p53-binding site which filled the space occupied by p53 helix.  
 
Figure 19 – PPX4 in the binding site of MDM2. 
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Figure 20 – Derivatives 11-16 in the binding site of MDM2. 
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Figure 21 – Derivatives 17-22 in the binding site of MDM2. 
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3.5. Evaluation of the inhibitory activity on p53:MDM2 interaction using 
yeast screening assays  
 
The inhibitory activity of the library of aminoxanthone derivatives was investigated 
using yeast-phenotypic assays developed for an initial screening of inhibitors of 
p53:MDM2 interaction75. This study was performed with the assistance of Master Ana 
Sara Gomes and with the supervision of Prof. Lucília Saraiva at UCIBIO, Laboratory of 
Microbiology, FFUP. The effectiveness of these yeast-screening assays for the 
identification of small-molecule inhibitors of p53:MDM2 interaction was displayed not only 
by testing nutlin-3a, a known small-molecule inhibitor of p53:MDM2 interaction, but also 
by the identification of pyranoxanthone LEM1 as a promising inhibitor of the p53:MDM2 
interaction, for which the molecular mechanism of action was confirmed using human 
tumor cell lines75. In this context, using the yeast-growth inhibition assay, the effect of 
aminoxanthone derivatives 12, 13, 15, 16, 19, 20, and 22 on the growth of the yeast 
expressing human p53 and MDM2 proteins was evaluated at concentrations of 1 μM and 
10 μM. Based on the results represented in Figure 22, a significant difference between 
the percentages of growth of the yeast cells treated with DMSO and the yeast treated with 
the compounds was not observed at 1 μM and 10 μM.  
 
Figure 22 - Effect of 12, 13, 15, 16, 19, 20 and 22 at concentrations of 1μM and 10μM on the growth of yeast 
co-expressing p53 and MDM2; results were plotted setting as 100% growth the number of CFUs with yeast 
co-expressing p53 and MDM2 incubated with DMSO only; data are mean ± SEM of four independent 
experiments; significantly different values are indicated (*P < 0.05). CFU = colony-forming unit; DMSO = 
dimethylsulfoxide; SEM = standard error of the mean. 
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These results suggested that these seven aminoxanthone derivatives did not show 
an inhibitory activity on p53:MDM2 interaction. 
Further studies will pursuit with the investigation of the effect of aminoxanthones 
on p73:MDM2 interaction and in tumor cell growth inhibition. 
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CHAPTER 4 - CONCLUSIONS 
  The p53:MDM2 constitutes a valuable target for identification of activators of the 
p53-dependent pathway. The identification of small-molecule inhibitors of 
p53:MDM2/MDMX interaction may restore the antiproliferative activity of p53 constituting 
an appealing approach for cancer therapy. Several new small-molecules inhibitors of 
p53:MDM2/MDMX interaction have been described. In last years, dual inhibitors have 
emerged due to their ability of fully activating p53-dependent pathway by simultaneous 
inhibition of MDM2 and MDMX. 
Among the strategies and techniques used to identify small-molecule inhibitors of 
p53:MDM2 interaction, the structure-based design and yeast-screening assays were used 
in this dissertation.  
The reaction conditions used for the reductive amination of the carbaldehydic 
xanthone LEM2 allowed a successful synthesis of a library of aminoxanthone derivatives. 
Reductive amination of LEM2 was quite sensitive to reagent and solvent conditions and 
the STAB/THF system was successful in providing the desirable aminoxanthones. The 
spectroscopic techniques IR and NMR put in evidence the desirable transformations. 
With the objective of predicting the binding affinity of these derivatives and the 
respective xanthonic building blocks towards MDM2, docking simulation studies were 
performed. These studies have shown that the aminoxanthone derivatives presented a 
higher binding affinity than the respective building blocks. However, the inhibitory activity 
of these derivatives against the p53:MDM2 interaction using yeast-screening assays was 
not concordant with the promising docking results. The results of biological activity 
allowed to conclude that the molecular hybridization strategy of coupling an amine moiety 
of known inhibitors of p53:MDM2 interaction at position C-1 was not successful in 
providing inhibitors of this interaction. Nevertheless, the presence of an amine group at 
position C-1 seems to be essential for the identification of small-molecules with antitumor 
activity and similar scaffolds. In fact, the thioxanthones lucanthone and hycanthone102, 
and the antraquinone mitoxantrone are antitumor agents that present an aliphatic amine 
group at position C-1 of the tricyclic scaffold. Since LEM2 is an inhibitor of p73:MDM2 
interaction with a weak effect on p53:MDM2 interaction (unpublished data), the 
investigation of the effect of LEM2 derivatives on p73:MDM2 interaction should be 
performed in future work. 
Overall, these results may contribute to the study of the most favorable structural 
requirements in order to obtain novel and potent p53/p73 activators with an antitumor 
effectiveness. 
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CHAPTER 5 - MATERIAL AND METHODS 
 
5.1. General Methods 
 
All reagents and solvents were purchased from Sigma Aldrich, and had no further 
purification process. Solvents were evaporated using rotary evaporator under reduced 
pressure, Buchi Waterchath B-480. All reactions were monitored by TLC carried out on 
precoated plates with 0.2 mm of thickness using Merck silica gel 60 (GF254). The UV light 
at 254 and 365 nm and a solution of ninhydrin in ethanol 3 mg/ml (activated by heat) were 
used for visualization of chromatograms.  Microwave (MW) reactions were performed in 
glassware open vessel reactors in a MicroSYNTH 1600 Microwave Labstation from 
Millestone (ThermoUnicam, Portugal). The internal reaction temperature was controlled by 
a fiber-optic probe sensor. Purification of the synthesized compounds was performed by 
chromatography flash column using Merck silica gel 60 (0.040-0.063 mm), 
chromatography flash cartridge (GraceResolv®, Grace Company, Deerfield, IL, USA), 
Discovery® DSC-SCX SPE cationic exchange cartridge. Melting points (mp) were 
measured in a Köfler microscope and are uncorrected. Infrared (IR) spectra were obtained 
in KBr microplates in a Fourier transform infrared spectroscopy spectrometer Nicolet iS10 
from Thermo Scientific with Smart OMNI-Transmisson accessory (Software OMNIC 8.3) 
(cm-1). NMR spectra were performed in University of Aveiro, Department of Chemistry, 
and were taken in CDCl3 (Deutero GmbH) at room temperature on Bruker Avance 300 
spectrometer (300.13 MHz for 1H and 75.47 MHz for 13C). 
Qualitative GC-MS analyses were performed by Dr. Sara Cravo, Department of 
Chemistry, Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, 
University of Porto. The analyses were performed on a Trace GC 2000 Series 
ThermoQuest gas chromatography equipped with ion-trap GCQ Plus ThermoQuest 
Finnigan mass detector. Chromatographic separation was achieved using a capillary 
columm (30m × 0.25 mm × 0.25 µm, cross-linked 5% diphenyl and 95% dimethyl 
polysiloxane) from Thermo Scientific™ and high-purity helium C-60 as carrier gas. An 
initial temperature of 80ºC was maintained for 1 min, increased to 310ºC at 10ºC/min, and 
held for 5 min giving a total run time of 33 min. The flow of the carrier gas was maintained 
at 1.5 ml/min. The injector port was set at 280ºC. Analyses were performed with splitless 
injection in the full-scan mode in the scan range of m/z 50-700. For derivatized samples 
30 µL of MSTFA were added and samples heated at 80ºC for 30 min. to accomplish 
silylation. An aliquot of 1 µl of the derivatized extract was injected into the GC-MS system. 
 
 
 84 
 
5.2. Synthesis of the carbaldehydic xanthone LEM2 
 
5.2.1. Synthesis of benzophenone intermediate 3, (2-hydroxy-3,4-dimethoxy-6-
methylphenyl) methoxyphenyl) methanone  
 
AlCl3 anhydrous (18.3 g, 137.2 mmol) was added to a dry ether solution (200 ml) of 
2-methoxybenzoyl chloride (11.2 g, 65.85 mmol) and trimethoxytoluene (10 g, 54.88 
mmol). The resulting deep red mixture was stirred at room temperature for 5 h. The 
reaction was monitored using n-hexane/ethyl acetate in a proportion of 7:3. After 
completing the reaction, the suspension was acidified with HCl 5M and extracted with 
chloroform. The evaporation of the dried organic layer gave a brown oil103.  
 
5.2.2. Synthesis of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4): cyclization of 
benzophenone intermediate 3  
 
To a solution of NaOH (48 g, 1.2 mol) in MeOH (240 ml) and water (160 ml), the 
crude material containing 2-hydroxy-3,4-dimethoxy-6-methylphenyl) methoxyphenyl) 
methanone (3) was added. The mixture was submitted to 6 h of microwave (MW) 
irradiation at 300 W of potency. The evolution of reaction was made using n-hexane/ethyl 
acetate in a proportion of 7:3. After completing the reaction and cooling at room 
temperature, the white solid formed was filtered, washed with methanol and dried. The 
solid of 3,4-diethyl-1-methyl-9H-xanthen-9-one (4, 2.52 g) was crystallized from ethyl 
acetate/n-hexane (procedure adapted from 87). 
 
5.2.3. Synthesis of 1-(dibromomethyl)-3,4-dimethoxy-9H-xanthen-9-one (5) 
 
A mixture of 3,4-diethyl-1-methyl-9H-xanthen-9-one (2.52 g, 9.32 mmol), N-
bromosuccinimide (3.32 g, 2.0 eq.) and benzoyl peroxide (0.68g, 0.3 eq.) in carbon 
tetrachloride (25 ml) was refluxed for 2 h. The chromatographic system n-hexane/ethyl 
acetate in a proportion of 8:2, was used to control the progression of the reaction. Once 
completed the reaction, the suspension was cooled at 0°C and stirred 1-2 h. The 
precipitate was filtered and washed with cold carbon tetrachloride. The mother liquor was 
evaporated and then purified by a flash column chromatography (silica gel, n-hexane/ethyl 
acetate in gradient) using several proportions to obtain a white solid of 1-(dibromomethyl)-
3,4-dimethoxy-9H-xanthen-9-one (5, 3.14 g, 80%). The experimental procedure was 
adapted from 89. 
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5.2.4.  Synthesis of 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2) 
 
A mixture of the dibromoxanthone derivative 5 (3.14 g, 7.34 mmol) and ionic liquid, 
1-butyl-3-methylimidazolium tetrafluoroborate mixed with water (6 ml, 5:1) was heated at 
100°C with stirring for 2.5 h. The mobile phase n-hexane/ethyl acetate 7:3 was used to 
control the progression of reaction. The reaction was allowed to cool, diluted in water, and 
extracted with ethyl acetate (3 x 200 ml). The organic layer was dried with anhydrous 
sodium sulphate, concentrated under reduced pressure and the crude material was 
purified by flash column chromatography (silica gel, n-hexane/ethyl acetate in gradient). A 
light yellow solid corresponding to 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde was 
obtained (LEM2, 1.33 g, 64%). The experimental procedure described here was adapted 
from 90.    
 
3,4-Dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2); mp > 330°C (ethyl acetate); 
IR (KBr): max= 3433, 2927, 1684, 1649, 1580, 1464, 1320, 1132, 758; 
1H NMR (CDCl3, 
300.13 MHz): δ = 11.21 (1H, s, H-1’), 8.31 (1H, dd, J = 8.0 and 1.7 Hz, H-8), 7.77 (1H, 
ddd, J = 8.5, 7.0, and 1.7 Hz, H-6), 7.60 (1H, dd, J = 8.5 and 0.8 Hz, H-5), 7.56 (1H, s, H-
2), 7.43 (1H, ddd, J = 8.0, 7.0 and 0.8 Hz, H-7), 4.11 (3H, s, H-4), 4.07 (3H, s, H-3); 13C-
NMR (CDCl3, 75.47 MHz): δ = 192.8 (C-1’), 177.9 (C-9), 156.3 (C-3), 155.5 (C-10a), 150.9 
(C-4a), 140.7 (C-4), 135.1 (C-6), 133.5 (C-1), 126.7 (C-8), 124.5 (C-7), 121.9 (C-8a), 
117.8 (C-5), 116.1 (C-9a), 108.5 (C-2), 61.8 (C-4’’), 56.6 (C-3’’). HRMS-ESI m/z calc for 
C16H12O5 [M+H]
+ 284.06847, found: 285.07627. 
  
5.3. Synthesis of aminoxanthone derivatives of carbaldehydic xanthone 
LEM2 
 
5.3.1. General procedure for reductive amination 
 
5.3.1.1. Synthesis of 1-(hydroxymethyl)-3,4-dimethoxy-9H-xanthen-9-one (11) 
 
The 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2, 20 mg, 0.071 
mmol) and the amine precursors (0.099 mmol) were dissolved/suspended in methanol 
(5ml) and the MP-BH4 (112.7 mg, 0.281 mmol, loading 2.5 mmol/g) was added to the 
reaction mixture. The reaction mixture was stirred at room temperature and monitored 
using the mobile phase n-hexane/ ethyl acetate, 7:3. A solid phase extraction with a cation 
exchange cartridge Discovery® DSC-SCX was performed in work-up of the crude 

 86 
 
material, following the steps: activation of the cartridge with methanol (50 ml); loading the 
cartridge with the sample; elution with NH3 2% in methanol. The non-basic and basic 
fractions were controlled by TLC using the mobile phase n-hexane/ ethyl acetate, 7:3. The 
non-basic fractions were gathered and concentrated under reduced pressure. The solid 
thus obtained was purified by a chromatography flash cartridge (Grace Resolv®) with n-
hexane/ethyl acetate in gradient. The fractions containing the derivative 11 were gathered 
and concentrated under reduced pressure to furnish a white solid of 1-(hydroxymethyl)-
3,4-dimethoxy-9H-xanthen-9-one (11). This procedure was adapted from **. 
 
1-(Hydroxymethyl)-3,4-dimethoxy-9H-xanthen-9-one (11); mp 187-189°C (ethyl acetate); 
IR (KBr): max (cm
-1) = 3496, 3460, 2938, 1638, 1618, 1601, 1584, 1510, 1466, 1405, 
1327, 1132, 1093, 1053, 993, 765, 755; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.32 
(1H, dd, J = 8.0 and 1.7 Hz, H-8), 7.75 (1H, ddd, J = 8.5, 7.0, and 1.7 Hz, H-6), 7.59 (1H, 
dd, J = 8.4 and 0.9 Hz, H-5), 7.41 (1H, ddd, J = 8.0, 7.1 and 0.9 Hz, H-7), 6.98 (1H, s, H-
2), 4.95 (2H, s, H-1’); 4.03 (3H, s, H-4), 4.01 (3H, s, H-3); 13C-NMR (CDCl3, 75.47 MHz): δ 
(ppm) = 179.0 (C-9), 156.7 (C-3), 155.4 (C-10a), 152.3 (C-4a), 139.3 (C-1), 136.1 (C-1), 
134.9 (C-6), 126.7 (C-8), 124.2 (C-7), 121.9 (C-8a), 117.7 (C-5), 114.8 (C-9a), 110.3 (C-
2), 65.7 (C-1’), 61.6 (C-4’’), 56.4 (C-3’’). EI-MS (70 eV) m/z (rel. intensity, %): 286.1 (M+, 
56), 257.1 (100), 242.1 (55), 213.1 (86), 211.0 (39), 115.1 (43), 92.1 (16), 77.1 (62), 51.0 
(72).  
  
5.3.1.2. General synthesis of the aminoxanthone derivatives of LEM2 
 
The 3,4-dimethoxy-9-oxo-9H-xanthene-1-carbaldehyde (LEM2, 40 mg, 0.141 
mmol) and the amine precursors (0.197mmol) (Table 15) were dissolved/suspended in 
THF (3 ml) and added to the reaction mixture the sodium triacetoxyborohydride (119.3 
mg, 0.563 mmol). After adding the acetic acid (24 μl, 0.423 mmol), the mixture was stirred 
at r.t. overnight, under N2. For monitoring the synthesis of aminoxanthone derivatives by 
TLC, two chromatographic systems were used: n-hexane/ ethyl acetate, 7:3; 
methanol/TEA 100:0.1 for amines 12-18 and chloroform/acetone/TEA 5:5:0.1 for amines 
19-22.  
The crude product obtained from the reductive amination of each amine precursor 
was subjected to different work-up strategies. The experimental procedure was adapted 
from 94. 
 
 

** Biotage. (2006). Synthesis and Purification CATALOG 58-113. 
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5.3.2. Synthesis and structure elucidation  
 
5.3.2.1. Synthesis of 3,4-dimethoxy-1-(((2-morpholinoethyl)amino)methyl)-9H-
xanthen-9-one (12) and 1-(((3-(dimethylamino)propyl)methyl)amino) 
methyl)-3,4-dimethoxy-9H-xanthen-9-one (13) 
 
Compounds 12 and 13 were synthesized based on the protocol described on 
section 3.1.2. After the completion of reaction, a liquid-liquid extraction under acidic and 
basic solutions was performed. Initially, the crude material was basified with NaOH 5% 
and extracted with chloroform (3 x 10 ml). The crude product contained in the resulting 
organic layer was then extracted with HCl 5M (3 x 30 ml). The resulting aqueous layer 
was basified with NaOH 20% and extracted with chloroform (3 x 100 ml). The dried 
organic layer was concentrated under reduced pressure and the crude product was 
purified by a column chromatography (chloroform/acetone/NH3 in gradient) yielding a light 
green solid of 3,4-dimethoxy-1-(((2-morpholinoethyl)amino)methyl)-9H-xanthen-9-one (12, 
31.6 mg, 56%) and a white solid of 1-(((3-(dimethylamino)propyl)methyl)amino)methyl)-
3,4-dimethoxy-9H-xanthen-9-one (13, 33.3 mg, 62%).    
 
3,4-Dimethoxy-1-(((2-morpholinoethyl)amino)methyl)-9H-xanthen-9-one (12); mp 125-126 
°C (chloroform); IR (KBr): max (cm
-1) = 3432, 3303, 2961, 2853, 2816, 1643, 1615, 1584, 
1470, 1412, 1328, 1313, 1296, 1276, 1257, 1232, 1146, 1132, 1117, 1076, 1031, 921, 
809, 769, 755, 669; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.25 (1H, dd, J = 8.0 and 
1.6 Hz, H-8), 7.72 (1H, ddd, J = 8.1, 7.0, and 1.6 Hz, H-6), 7.57 (1H, dd, J = 8.4 and 0.8 
Hz, H-5), 7.38 (1H, ddd, J = 8.0, 7.1 and 0.9 Hz, H-7), 7.09 (1H, s, H-2), 4.34 (2H, s, H-1’); 
4.04 (3H, s, H-4), 4.01 (3H, s, H-3), 3.66 (4H, t, J = 4.6 Hz, H-5’), 2.90 (2H, t, J = 6.1 Hz, 
H-2’), 2.60 (2H, t, J = 6.1 Hz, H-3’), 2.47 (4H, t, J = 4.3 Hz, H-4’); 13C-NMR (CDCl3, 75.47 
MHz): δ (ppm) = 178.0 (C-9), 156.5 (C-3), 155.3 (C-10a), 152.1 (C-4a), 137.0 (C-1), 136.0 
(C-4), 134.6 (C-6), 126.5 (C-8), 124.1 (C-7), 122.1 (C-8a), 117.7 (C-5), 114.6 (C-9a), 
111.6 (C-2), 67.0 (C-5’), 61.5 (C-4’’), 57.4 (C-2’), 56.4 (C-3’’), 53.7 (C-1’), 53.5 (C-4’), 45.3 
(C-3’). 
 
1-(((3-(Dimethylamino)propyl)methyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one 
(13); mp 84-85 °C (chloroform); IR (KBr): max (cm
-1) = 3436, 2938, 2857, 2817, 1650, 
1615, 1599, 1584, 1464, 1428, 1414, 1346, 1314, 1274, 1259, 1233, 1154, 1129, 1084, 
1039, 997, 925, 913, 893, 765, 674; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.25 (1H, 
dd, J = 8.0 and 1.6 Hz, H-8), 7.69 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.54 (1H, dd, J 

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= 7.4 and 0.7, H-5), 7.53 (1H, s, H-2), 7.35 (1H, ddd, J = 8.0, 7.1 and 1.0 Hz, H-7), 4.36 
(2H, s, H-1’); 4.05 (3H, s, H-4), 4.02 (3H, s, H-3), 2.65 (2H, t, J = 7.2 Hz, H-3’), 2.44 (2H, t, 
J = 7.5 Hz, H-5’), 2.39 (3H, s, H-2’), 2.28 (6H, s, H-6’), 1.82 (2H, m, J = 7.3 Hz, H-4’); 13C-
NMR (CDCl3, 75.47 MHz): δ (ppm) = 178.1 (C-9), 156.6 (C-3), 155.2 (C-10a), 151.9 (C-
4a), 135.2 (C-1), 135.0 (C-4), 134.2 (C-6), 126.6 (C-8), 123.9 (C-7), 122.4 (C-8a), 117.6 
(C-5), 114.5 (C-9a), 109.0 (C-2), 61.5 (C-4’’), 60.1 (C-1’), 57.8 (C-5’), 56.4 (C-3’’), 56.1 (C-
3’), 45.3 (C-6’), 42.5 (C-2’), 25.3 (C-4’). 
 
5.3.2.2. Synthesis of 1-(((2-(diethylamino)ethyl)amino)methyl)-3,4-dimethoxy-9H-
xanthen-9-one (14) 
 
Compound 14 was synthesized based on the procedure described in 3.1.2. After 
the completion of reaction, a liquid-liquid extraction of the crude material was performed 
only with chloroform (3 x 10 ml). The organic layers were gathered, washed with water (10 
ml), dried over anhydrous sodium sulphate and was concentrated under reduced 
pressure. The solid obtained was purified by solid phase extraction with a cation 
exchange cartridge Discovery® DSC-SCX, following an identical procedure of section 
3.1.1. for derivative 11. The non-basic and basic fractions were controlled by TLC using 
methanol/TEA 100:0.1 as mobile phase. The basic fractions were gathered and 
evaporated under reduced pressure. Then, the crude material was purified by a 
chromatography flash cartridge (chloroform/acetone/TEA in gradient), resulting in a pure 
green solid of 1-(((2-(diethylamino)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one 
(14, 21.3 mg, 40%). 
 
1-(((2-(Diethylamino)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (14); mp 68-69 
°C (chloroform); IR (KBr): max (cm
-1) = 3444, 3316, 2968, 2940, 2841, 1645, 1615, 1600, 
1585, 1567, 1467, 1435, 1409, 1313, 1258, 1232, 1198, 1131, 1075, 1031, 983, 937, 767, 
752, 685; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.27 (1H, dd, J = 8.0 and 1.4 Hz, H-8), 
7.71 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.56 (1H, dd, J = 8.4 and 0.7 Hz, H-5), 7.37 
(1H, ddd, J = 8.0, 7.1 and 1.0 Hz, H-7), 7.14 (1H, s, H-2), 4.39 (2H, s, H-1’); 4.05 (3H, s, 
H-4), 4.01 (3H, s, H-3), 2.87 (2H, t, J = 6.4 Hz, H-2’), 2.68 (2H, t, J = 6.4 Hz, H-3’), 2.55 
(4H, m, J = 7.1 Hz, H-4’), 1.01 (6H, t, J = 7.1 Hz, H-5’); 13C-NMR (CDCl3, 75.47 MHz): δ 
(ppm) = 178.1 (C-9), 156.5 (C-3), 155.3 (C-10a), 152.1 (C-4a), 137.4 (C-1), 135.8 (C-4), 
134.5 (C-6), 126.6 (C-8), 124.0 (C-7), 122.2 (C-8a), 117.7 (C-5), 114.5 (C-9a), 111.1 (C-
2), 61.5 (C-4’’), 56.4 (C-3’’), 53.4 (C-3’), 52.4 (C-1’), 46.9 (C-4’), 46.8 (C-2’), 11.6 (C-5’). 
EI-MS (70 eV) m/z (rel. intensity, %): 383.8 (M+, 2), 368.4 (8), 355.0 (9), 326.4 (3), 301.1 
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(9), 300.1 (21), 298.1 (40), 269.2 (45), 250.3 (6), 225.1 (27), 208.4 (10), 155.2 (6), 115.1 
(22), 86.2 (100), 58.1 (45). 
 
5.3.2.3. Synthesis of 1-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3,4-dimethoxy-
9H-xanthen-9-one (15) 
 
Compound 15 was synthesized based on the procedure described in 3.1.2. After 
the completion of reaction, the crude material was subjected to a similar liquid-liquid 
extraction procedure described in section 3.2.1. The organic layer resulting from the 
liquid-liquid extraction was dried and concentrated under reduced pressure furnishing a 
yellow solid corresponding to 1-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3,4-dimethoxy-
9H-xanthen-9-one  (15, 38 mg, 68%). 
 
1-((4-(2-Hydroxyethyl)piperazin-1-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one  (15); mp 
129-130 °C (chloroform); IR (KBr): max (cm
-1) = 3423, 2932, 2804, 2759, 1652, 1617, 
1601, 1586, 1569, 1505, 1466, 1448, 1405, 1345, 1315, 1268, 1256, 1234, 1160, 1129. 
1065, 1033, 996, 918, 896, 765, 754; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.25 (1H, 
dd, J = 8.0 and 1.6 Hz, H-8), 7.68 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.53 (1H, dd, J 
= 8.4 and 0.7 Hz, H-5), 7.48 (1H, s, H-2), 7.35 (1H, ddd, J = 8.0, 7.1 and 1.0 Hz, H-7), 
4.32 (2H, s, H-1’), 4.03 (3H, s, H-4), 4.01 (3H, s, H-3), 3,63 (2H, t, J = 5.4 Hz), 2.58 (2H, t, 
J = 5.4 Hz); 13C-NMR (CDCl3, 75.47 MHz): δ (ppm) = 178.1 (C-9), 156.5 (C-3), 155.2 (C-
10a), 152.0 (C-4a), 138.8 (C-1), 134.8 (C-4), 134.2 (C-6), 126.6 (C-8), 123.9 (C-7), 122.5 
(C-8a), 117.5 (C-5), 114.6 (C-9a), 108.2 (C-2), 61.5 (C-4’’), 60.2 (C-1’), 59.3 (C-5’), 57.7 
(C-4’), 56.2 (C-3’’), 53.5 (C-3’), 53.2 (C-2’). EI-MS (70 eV) m/z (rel. intensity, %): 399.0 
(M+, 8), 312.0 (49), 311.1 (17), 310.1 (11), 270.1 (35), 269.1 (54), 255.1 (31), 225.2 (28), 
176.1 (24), 139.1 (6), 130.1 (17), 111.1 (38), 98.1 (100), 73.1 (70), 56.1 (33). 
 
5.3.2.4. Synthesis of 4-((3,4-dimethoxy-9-oxo-9H-xanthen-1-yl)methyl) piperazin-
2-one (16), 1-((5-amino-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3,4-
dimethoxy-9H-xanthen-9-one (17), and 3,4-dimethoxy-1-(piperidin-1-
ylmethyl)-9H-xanthen-9-one (18) 
 
Compounds 16, 17, and 18 were synthesized based on the procedure described in 
3.1.2. After the completion of reaction, a liquid-liquid extraction of the crude material was 
performed only with chloroform. The resulting organic layer was dried and concentrated 
under reduced pressure. The solid thus obtained was subjected to a solid phase 

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extraction with cation exchange cartridge Discovery® DSC-SCX, following an identical 
procedure described in section 3.1.1. The non-basic and basic fractions were controlled 
by TLC using methanol/TEA 100:0.1 as mobile phase. The basic fractions containing a 
single spot of 16 and 18 were gathered and concentrated under reduced pressure, 
furnishing a pure orange solid of 4-((3,4-dimethoxy-9-oxo-9H-xanthen-1-
yl)methyl)piperazin-2-one (16, 18.2 mg, 35%) and a pure yellow solid of 3,4-dimethoxy-1-
(piperidin-1-ylmethyl)-9H-xanthen-9-one (18, 28.8 mg, 58%). The crystallization from the 
fraction with NH3 2% in methanol resulted in a pure white solid of 1-((5-amino-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one (17, 21 mg, 36%). 
 
4-((3,4-Dimethoxy-9-oxo-9H-xanthen-1-yl)methyl)piperazin-2-one (16); mp 245-247 °C 
(methanol); IR (KBr): max (cm
-1) = 3547, 3421, 3280, 2958, 2923, 2852, 1675, 1646, 
1617, 1599, 1585, 1569, 1505, 1465, 1430, 1380, 1350, 1320, 1259, 1232, 1129, 1108, 
1060, 1000, 978, 927, 765; 1H NMR (DMSO, 300.13 MHz): δ (ppm) = 8.13 (1H, dd, J = 
8.0 and 1.5 Hz, H-8), 7.82 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.65 (1H, dd, J = 8.4 
and 0.6, H-5), 7.45 (1H, ddd, J = 8.0, 7.1 and 1.0 Hz, H-7), 7.36 (1H, s, H-2), 4.24 (2H, s, 
H-1’); 3.98 (3H, s, H-4), 3.90 (3H, s, H-3), 3.20 (2H, t, J = 5.3 Hz, H-3’), 3.13 (2H, s, H-2’), 
2.66 (2H, t, J = 5.3 Hz, H-4’); 13C-NMR (DMSO, 75.47 MHz): δ (ppm) = 176.7 (C-9), 168.0 
(C-4’), 156.2 (C-3), 154.6 (C-10a), 151.8 (C-4a), 136.9 (C-1), 135.0 (C-4), 134.7 (C-6), 
126.1 (C-8), 124.3 (C-7), 121.8 (C-8a), 117.7 (C-5), 113.7 (C-9a), 109.2 (C-2), 60.9 (C-
4’’), 58.5 (C-1’), 57.2 (C-3’), 56.3 (C-3’’), 48.7 (C-2’), 30.7 (C-5’).  
 
1-((5-Amino-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dimethoxy-9H-xanthen-9-one 
(17); mp 171-172 °C (methanol); IR (KBr): max (cm
-1) = 3463, 3387, 2927, 2866, 1654, 
1617, 1600, 1585, 1567, 1504, 1466, 1416, 1362, 1343, 1315, 1257, 1232, 1187, 1130, 
1062, 1017, 998, 927, 765; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.26 (1H, dd, J = 8.0 
and 1.4 Hz, H-8), 7.69 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.57 (1H, s, H-2), 7.54 
(1H, dd, J = 8.4 and 0.7 Hz, H-5), 7.35 (1H, ddd, J = 8.0, 7.1 and 1.0 Hz, H-7), 6.99 (1H, t, 
J = 7.7 Hz, H-6’), 6.57 (1H, d, J = 7.8 Hz, H-7’), 6.53 (1H, d, J = 7.6 Hz, H-7’), 4.48 (2H, s, 
H-1’); 4.02 (3H, s, H-4), 3.97 (3H, s, H-3), 3.81 (2H, s, H-3’), 2.93 (2H, t, J = 5.9 Hz, H-2’), 
2.66 (2H, t, J = 5.9 Hz, H-4’); 13C-NMR (CDCl3, 75.47 MHz): δ (ppm) = 178.2 (C-9), 156.7 
(C-3), 155.2 (C-10a), 151.9 (C-4a), 144.1 (C-8’), 139.3 (C-1), 136.3 (C-5’), 134.8 (C-4), 
134.2 (C-6), 126.6 (C-8), 126.4 (C-9’), 123.8 (C-7), 122.5 (C-8a), 119.5 (C-6’), 117.6 (C-
5), 117.1 (C-7’), 114.5 (C-9a), 112.7 (C-10’), 108.0 (C-2), 61.5 (C-4’’), 60.1 (C-1’), 56.7 (C-
3’), 56.3 (C-3’’), 51.0 (C-2’), 24.9 (C-4’). 
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3,4-Dimethoxy-1-(piperidin-1-ylmethyl)-9H-xanthen-9-one (18); mp 108-109 °C 
(chloroform); IR (KBr): max (cm
-1) = 3432, 2929, 2853, 1653, 1617, 1600, 1568, 1502, 
1465, 1447, 1405, 1344, 1315, 1257, 1233, 1188, 1130, 1063, 999, 895, 765; 1H NMR 
(CDCl3, 300.13 MHz): δ (ppm) = 8.25 (1H, dd, J = 8.0 and 1.6 Hz, H-8), 7.66 (1H, ddd, J = 
8.5, 8.0, and 1.6 Hz, H-6), 7.56 (1H, s, H-2), 7.52 (1H, dd, J = 8.3 and 0.7 Hz, H-5), 7.33 
(1H, ddd, J = 7.9, 7.1 and 0.9 Hz, H-7), 4.26 (2H, s, H-1’); 4.03 (3H, s, H-4), 4.01 (3H, s, 
H-3), 2.57 (4H, t, J = 4.6 Hz, H-2’), 1.65 (4H, m, J = 5.5 Hz, H-3’), 1,50 (2H, m, J = 5.5 Hz, 
H-4’); 13C-NMR (CDCl3, 75.47 MHz): δ (ppm) = 177.5 (C-9), 156.1 (C-3), 154.7 (C-10a), 
151.3 (C-4a), 138.9 (C-4), 134.2 (C-1), 133.8 (C-6), 126.0 (C-8), 123.3 (C-7), 121.9 (C-
8a), 117.1 (C-5), 113.9 (C-9a), 107.8 (C-2), 60.8 (C-4’’), 56.1 (C-3’’), 55.7 (C-2’), 54.3 (C-
1’), 25.7 (C-3’), 23.8 (C-4’). EI-MS (70 eV) m/z (rel. intensity, %): 352.9 (M+, 6), 309.9 (8), 
280.2 (9), 268.0 (27), 255.0 (23), 253.1 (15), 225.0 (13), 184.0 (9), 127.1 (14), 126.0 (6), 
84.0 (100), 56.0 (14). 
 
5.3.2.5. Synthesis of 1-(((4-fluorobenzyl)amino)methyl)-3,4-dimethoxy-9H-
xanthen-9-one (19), 1-(((4-chlorobenzyl)amino)methyl)-3,4-dimethoxy-9H-
xanthen-9-one (20), 1-(((1-(4-chlorophenyl)ethyl)amino)methyl)-3,4-
dimethoxy-9H-xanthen-9-one (21), and 1-(((4-bromobenzyl)amino)methyl)-
3,4-dimethoxy-9H-xanthen-9-one (22) 
 
Compounds 19, 20, 21, and 22 were synthesized based on the procedure 
described in 3.1.2. After the completion of reaction, the crude material was subjected to a 
similar liquid-liquid extraction procedure described in section 3.2.1. for amines 12 and 13. 
The organic layer resulting from the extraction with HCl 5M, containing the halogenated 
aromatic derivatives, was dried and concentrated under reduced pressure. Afterwards, a 
solid phase extraction with cation exchange cartridge Discovery® DSC-SCX was carried 
out, following an identical procedure described in section 3.1.1. The non-basic and basic 
fractions were controlled by TLC using chloroform/acetone/TEA 5:5:0.1 as mobile phase. 
The basic fractions containing only a single spot corresponding to these aminoxanthone 
derivatives were gathered and concentrated under reduced pressure. It was obtained a 
pure light yellow solid of 1-(((4-chlorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-
one (20, 33 mg, 57%) and a pure white solid of 1-(((4-fluorobenzyl)amino)methyl)-3,4-
dimethoxy-9H-xanthen-9-one  (19, 22.5 mg, 41%), 1-(((1-(4-chlorophenyl)ethyl)amino) 
methyl)-3,4-dimethoxy-9H-xanthen-9-one (21, 37.5 mg, 63%) and 1-(((4-bromobenzyl) 
amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (22, 44.5 mg, 70%). 
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1-(((4-Fluorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (19); mp 163-165 °C 
(methanol); IR (KBr): max (cm
-1) = 3426, 3322, 2921, 2853, 1645, 1614, 1600, 1584, 
1563, 1507, 1467, 1429, 1405, 1329, 1312, 1260, 1233, 1217, 1193, 1132, 1089, 1073, 
1010, 974, 933, 815, 765, 685; 1H NMR (CDCl3, 300.13 MHz): δ = 8.28 (1H, dd, J = 8.0 
and 1.6 Hz, H-8), 7.71 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.55 (1H, dd, J = 8.5 and 
0.8 Hz, H-5), 7.40 (1H, ddd, J = 8.0, 7.0 and 0.8 Hz, H-7), 7.36 (2H, m, H-4’), 7.01 (2H, m, 
H-3’), 6.96 (1H, s, H-2), 4.30 (2H, s, H-1’), 4.01 (3H, s, H-4), 4.01 (3H, s, H-3), 3.85 (2H, s, 
H-2’); 13C-NMR (CDCl3, 75.47 MHz): δ = 178.1 (C-9), 160.3 (C-6’), 156.3 (C-3), 155.3 (C-
10a), 152.2 (C-4a), 138.6 (C-4), 135.9 (C-3’), 135.7 (C-1), 134.5 (C-6), 129.8 (C-5’), 126.7 
(C-8), 124.0 (C-7), 122.2 (C-8a), 117.7 (C-5), 115.3 (C-4’), 114.7 (C-9a), 110.9 (C-2), 61.5 
(C-4’’), 56.3 (C-3’’), 53.3 (C-1’), 52.5 (C-2’). EI-MS (70 eV) m/z (rel. intensity, %): 395.1 
(M+1, 3), 394.0 (M+, 6), 357.1 (12), 356.0 (47), 340.1 (11), 268.1 (10), 266.1 (24), 252.1 
(12), 222.2 (8), 139.2 (4), 110.1 (9), 109.1 (100), 83.1 (31), 73.0 (94). 
 
1-(((4-Chlorobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (20); mp 162-163°C; 
IR (KBr) (methanol): max (cm
-1) = 3443, 3315, 2919, 2847, 2779, 1655, 1615, 1595, 
1569, 1499, 1464, 1437, 1408, 1317, 1258, 1229, 1150, 1134, 1085, 1055, 1018, 972, 
895, 806, 762, 688; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.25 (1H, dd, J = 8.0 and 
1.6 Hz, H-8), 7.79 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.66 (2H, m, H-4’), 7.60 (1H, 
dd, J = 8.5 and 0.9 Hz, H-5), 7.43 (1H, ddd, J = 8.0, 7.0 and 0.9 Hz, H-7), 7.39 (1H, s, H-
2), 7.38 (2H, m, H-3’), 4.53 (2H, s, H-2’); 4.33 (2H, s, H-1’), 4.07 (3H, s, H-4), 4.01 (3H, s, 
H-3); 13C-NMR (CDCl3, 75.47 MHz): δ (ppm) = 179.6 (C-9), 157.0 (C-3), 155.5 (C-10a), 
152.0 (C-4a), 137.7 (C-4), 135.8 (C-1), 135.6 (C-6), 131.7 (C-5’), 129.5 (C-4’), 129.4 (C-
3’), 127.3 (C-6’), 126.6 (C-8), 124.6 (C-7), 121.3 (C-8a), 117.9 (C-5), 115.5 (C-2), 114.8 
(C-9a), 61.6 (C-4’’), 57.1 (C-3’’), 51.3 (C-1’), 50.7 (C-2’). EI-MS (70 eV) m/z (rel. intensity, 
%): 410.8 (M+1, 5), 409.8 (M+, 4), 406.9 (9), 357.8 (10), 355.2 (18), 319.0 (4), 306.0 (20), 
268.0 (100), 253.0 (25), 221.1 (14), 209.3 (28), 190.2 (18), 168.1 (10), 139.1 (24), 
125.1 (18), 89.0 (26), 77.1 (24).  
 
1-(((1-(4-Chlorophenyl)ethyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one  (21); mp 
163-164 °C; IR (KBr) (methanol): max (cm
-1) = 3425, 3310, 2936, 2847, 2730, 2665, 
1655, 1616, 1600, 1567, 1515, 1496, 1465, 1410, 1348, 1321, 1260, 1232, 1205, 1132, 
1076, 1018, 980, 922, 844, 766, 755, 670; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.26 
(1H, dd, J = 8.0 and 1.6 Hz, H-8), 7.79 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.70 (2H, 
m, H-5’), 7.59 (1H, dd, J = 8.5 and 0.8 Hz, H-5), 7.43 (1H, ddd, J = 8.0, 7.0 and 0.8 Hz, H-
7), 7.42 (2H, m, H-4’), 7.25 (1H, s, H-2), 4.54 (2H, s, H-1’); 4.27 (1H, q, J = 6.8 Hz, H-1’), 

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4.04 (3H, s, H-4), 4.01 (3H, s, H-3), 1.83 (3H, d, J = 6.8 Hz, H-3’); 13C-NMR (CDCl3, 75.47 
MHz): δ (ppm) = 179.6 (C-9), 156.8 (C-3), 155.4 (C-10a), 151.9 (C-4a), 137.6 (C-4), 135.5 
(C-6), 134.5 (C-1), 131.8 (C-7’), 129.8 (C-6’), 129.5 (C-5’), 127.3 (C-4’), 126.6 (C-8), 124.6 
(C-7), 121.3 (C-8a), 117.9 (C-5), 115.6 (C-2), 114.9 (C-9a), 61.6 (C-4’’), 58.9 (C-2’), 57.0 
(C-3’’), 50.2 (C-1’), 20.2 (C-3’). EI-MS (70 eV) m/z (rel. intensity, %): 423.8 (M+, 2), 407.6 
(4), 319.6 (3), 285.1 (27), 284.1 (100), 268.1 (24), 223.1 (19), 213.1 (27), 196.2 (19), 
155.0 (10), 139.0 (25), 103.0 (41), 77.0 (24). 
 
1-(((4-Bromobenzyl)amino)methyl)-3,4-dimethoxy-9H-xanthen-9-one (22); mp 161-162 °C 
(methanol); IR (KBr): max (cm
-1) = 3424, 3317, 2920, 2851, 1645, 1613, 1600, 1585, 
1562, 1467, 1430, 1405, 1328, 1314, 1256, 1235, 1151, 1132, 1090, 1073, 1029, 1010, 
971, 908, 798, 769, 687; 1H NMR (CDCl3, 300.13 MHz): δ (ppm) = 8.27 (1H, dd, J = 8.0 
and 1.6 Hz, H-8), 7.73 (1H, ddd, J = 8.5, 7.0, and 1.6 Hz, H-6), 7.58 (1H, dd, J = 8.5 and 
0.8 Hz, H-5), 7.48 (2H, m, H-4’), 7.39 (2H, m, H-3’), 7.38 (1H, ddd, J = 8.0, 7.0 and 0.8 Hz, 
H-7), 7.08 (1H, s, H-2), 4.31 (2H, s, H-1’); 4.01 (3H, s, H-4), 4.01 (3H, s, H-3), 3.88 (2H, s, 
H-2’); 13C-NMR (CDCl3, 75.47 MHz): δ (ppm) = 178.6 (C-9), 156.5 (C-3), 155.3 (C-10a), 
152.2 (C-4a), 136.4 (C-4), 136.2 (C-1), 134.9 (C-6), 131.8 (C-5’), 130.7 (C-4’), 128.4 (C-
3’), 126.6 (C-8), 124.2 (C-7), 121.9 (C-8a), 121.8 (C-6’), 117.7 (C-5), 114.7 (C-9a), 112.5 
(C-2), 61.6 (C-4’’), 56.7 (C-3’’), 52.7 (C-1’), 52.0 (C-2’). EI-MS (70 eV) m/z (rel. intensity, 
%): 454.0 (M+, 5), 358.2 (2), 357.1 (20), 356.1 (56), 326.1 (9), 295.1 (6), 269.2 (14), 266.1 
(23), 255.2 (11), 225.2 (7), 171.0 (22), 169.0 (30), 91.1 (11), 90.1 (40), 73.1 (100).  
 
5.4. Computational chemistry 
 
5.4.1. Preparation of a library of virtual xanthones and known inhibitors of 
p53:MDM2 interaction 
 
Twenty-two xanthone derivatives, four known inhibitors of p53:MDM2 interaction 
and one known inhibitor of p73:MDM2 interaction were drawn in ChemSketch (ACD/Labs 
2007) and subjected to energy minimization (using ArgusLab version 4.0.1 for Windows) 
by molecular mechanics using the force field method104. 
 
5.4.2. Docking studies 
 
Docking simulations in MDM2 (PDB code 1YCR) were undertaken in AutoDock 
embedded in PyRx – Virtual Screening Tool Software105. AutoDock Vina considered the 

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target conformation as a rigid unit while the ligands were allowed to be flexible and 
adaptable to the target. The software Vina searched for the lowest binding energy 
conformations and returned nine different conformations for each ligand.  
The following parameters were used in AutoDock Vina:  
 Exhaustiveness: 8 
 Vina search space (grid box) dimensions and positions in the MDM2: 
 
 The grid box was defined in PyRx by clicking and dragging the center and edges of 
the grid box in order to position it as shown in Figure 18.  
 The input files of the virtually designed xanthones were in mol format and pdb was 
chosen as the output file format. PyMOL version 0.99106 was used for visual inspection of 
results. 
 
5.5. Evaluation of the inhibitory activity on p53:MDM2 interaction using 
yeast-screening assays 
 
5.5.1. Yeast p53:MDM2 screening assay 
 
For the yeast growth-inhibition assay, the previously75 obtained Saccharomyces 
cerevisiae CG379 cells expressing p53 and/or MDM2 were used. Yeast cells were 
routinely grown in a minimal selective medium with 2% (w/w) glucose, 0.7% (w/w) yeast 
nitrogen base without amino acids from Difco (Quilaban, Sintra, Portugal) and all the 
amino acids required for yeast growth (50 μg ml-1) except leucine and tryptophan, to 
approximately 1 optical density at 600 nm (OD600). To induce expression of wt p53 and 
MDM2 proteins, yeast cells were diluted to 0.05 OD600 into selective induction medium 
with 2% (w/w) galactose and 2% (w/w) raffinose (instead of glucose), and incubated at 
30°C under continuous orbital shaking (200 rpm) for approximately 42 h. Yeast cell growth 
was analyzed by counting the number of CFU per mL (CFU mL-1) after 2 days incubation 
at 30°C on Sabouraud Dextrose Agar plates from Liofilchem (Frilabo, Porto, Portugal). 
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To evaluate the effect of tested compounds on cell growth, yeast cells were 
incubated in selective induction medium in the presence of 1 μm and 10 μm of 
compounds 12, 13, 15, 16, 19, 20 and 22, or 0.1% DMSO only for approximately 42 h (for 
analysis of p53:MDM2 interaction), at 30°C, under continuous shaking. Results were 
estimated considering 100% growth the number of CFU obtained with yeast co-
expressing p53 and MDM2 incubated with DMSO only. 
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